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Acinetobacter baumannii is a Gram-negative, non-fermenting bacillus that has developed into an 
important nosocomial pathogen, affecting millions of patients worldwide. The widespread ease 
of transmission, and ability to become multidrug resistant are some of the characteristics that, at 
the present time, have developed this bacterium into one of the most significant nosocomial 
pathogens today. The special ability it exhibits in developing resistance to a wide variety of 
known antimicrobial agents also helped make this a pathogen of profound importance in modern 
day medical microbiology. Carbapenems are used as a last resort for treating patients infected 
with resistant or multi-drug resistant (MDR) Acinetobacter baumannii. Hospitals have long 
served as reservoirs for the transmission of pathogenic bacteria, and this has become a problem 
in Kuwait. Unfortunately, very little research has been devoted exclusively to 
investigating Acinetobacter baumannii prevalence, resistance and pathogenicity in Kuwaiti 
Hospitals. Research on the local population in Kuwaiti Hospitals is important and beneficial to 
physicians, to help better diagnose and treat the infections, and prevent any outbreaks from 
spreading. 
 
 Aim: This study aimed to examine the resistance and identify the genotypic changes in the 
organism as it spreads through Mubarak Al-Kabeer Hospital.  
 
Methods: A total of 88 Acinetobacter baumannii samples were collected from the Mubarak Al-
Kabeer Hospital, over a three year period, 2006-2008, and they were identified phenotypically, 
by Vitek-2 systems, and then genotypically by PCR amplification of blaOXA-51-like gene. The 
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resistance to the carbapenems: imipenem and meropenem, was identified by use of the Minimal 
Inhibitory Concentration (MIC) test. Pulsed field gel electrophoresis (PFGE) was used to type 
the strains and classify them into clonal groups.  Identification of the blaOXA-51-like gene types of 
each of the isolates was done via gene sequencing.  
 
Results: All 88 isolates were identified as Acinetobacter baumannii by Vitek-2 system and were 
shown to carry a blaOXA-51-like gene. Resistance to Imipenem was found in 31.8% of the isolates, 
whereas resistance to meropenem was found in 23.8% of the isolates. Overall carbapenem 
resistance was observed in 55.7% of the total isolates, with a slight increase in resistance of 
isolated over the 3 years of collection. In all, there were 10 different blaOXA-51-like genes 
identified. The sequences of these genes suggested there was some degree of real-time evolution 
of the blaOXA-51-like genes during the study period. There were four main clonal clusters. There 
were three main European clones (blaOXA-66, blaOXA-69, and blaOXA-71) plus a new clone with 
blaOXA-51-like genes with sequences clustered around the blaOXA-98 gene.  
 
Conclusion: This study has shown four major clones were found in the hospital during the study 
period, three of the clones were closely associated with those found in Europe and elsewhere in 
the world, and one new clone, containing a blaOXA-98-like gene that appears to be more prevalent in 
this part of Asia. The gradual increase in resistance to carbapenems over the study period 
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The genus Acinetobacter has undergone major taxonomic changes over the last 30 years. 
Acinetobacter baumannii is the most significant species has and become one of the most 
troublesome pathogens for health care institutions the world over. Over the last 15 years, its 
clinical significance has been propelled by its notable ability to upregulate or acquire resistance 
determinants. This characteristic has made it into one of the main organisms threatening the 
current antibiotic era (Peleg et al., 2008).  
 
Recently, reports of strains of Acinetobacter baumannii, which are resistant to all known 
antibiotics, have increased, which suggest a troubling and worrying development that should be 
acted on swiftly by the international health care community and local governments (Peleg et al., 
2008). Another characteristic, alongside the increased resistance profile, which makes of 
Acinetobacter baumannii a distressing pathogen, is its ability to survive for prolonged periods of 
time, especially in hospital settings, thus increasing the capacity for nosocomial spread. 
 
The organism usually targets the most susceptible and immunocompromised patients. Hospital-
acquired pneumonia is considered to be the most common infection caused by this Acinetobacter 
baumannii but, more recently, infections which involve the central nervous system, skin and soft 
tissue, and bone have emerged as highly problematic for hospitals and health institutions (Peleg 
et al., 2008). 
 
Scientific and Public community interest in Acinetobacter has been raised considerably over 
recent years. There have been considerable advances made in our understanding of this 
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interesting organism in recent years. It is important to gain a brief understanding of the relevant 
clinical, microbiological, as well as the epidemiological characteristics of Acinetobacter 
baumannii, which is the most the most clinically relevant and wide spread species (Peleg et al., 
2008; Brisou and Prevot., 1954). 
 
1.1. History of the Genus Acinetobacter 
 
The history of the genus Acinetobacter dates back to the 1911, when Dutch microbiologist 
Beijerinck, described an organism named Micrococcus calcoaceticus that was isolated from soil 
by enrichment in a calcium acetate-containing minimal medium (Brisou and Prevot., 1954).  
 
The current genus designation, Acinetobacter (from the Greek ακινητο [akinetos], which means: 
non-motile), was proposed by Brisou and Prevot in 1954 to separate the motile from the non-
motile microorganisms within the genus Achromobacter.  
 
In 1968, this genus designation became more widely accepted. Baumann et al. first published a 
complete survey and concluded that the different species listed belonged to a single genus, this 
was when the name the name Acinetobacter was first proposed.  Further sub-classification into 
different species based on phenotypic characteristics was not possible (Baumann et al., 1968). 
All these discoveries resulted in the official acknowledgment of the genus Acinetobacter by the 




The genus Acinetobacter genus was first listed in the 1974 edition of Bergey’s Manual of 
Systematic Bacteriology (Peleg et al., 2008), with the description of a single species, 




The genus Acinetobacter, as is currently defined, is a Gram-negative, strictly aerobic, non-
fermenting, non-fastidious, non-motile, catalase-positive, oxidase-negative bacteria with a DNA 
G/C content of between 39% and 47%.  Based on more recent taxonomic data, it was proposed 
that members of the genus Acinetobacter should be classified in the new family Moraxellaceae 
within the order Gammaproteobacteria, which includes the genera Moraxella, Acinetobacter, 
Psychrobacter, and related organisms (Peleg et al., 2008, Rossau et al., 1991). 
 
A major breakthrough, however, in the long and complex history of the genus was achieved in 
1986 by Bouvet and Grimont, who based on DNA-DNA hybridization studies, distinguished 12 
DNA (hybridization) groups or genospecies, some of which were given formal species names, 
including A. baumannii, A. calcoaceticus, A. haemolyticus, A. johnsonii, A. junii, and A. lwoffii 
(Peleg et al., 2008, Bouvet and Grimont, 1986). More recently, 10 additional Acinetobacter 
species were described, including 3 species of human origin, A. parvus, A. schindleri, and A. 
ursingii (Nemec et al., 2001; Nemec et al., 2003) and 7 species isolated from activated sludge 
(recovered from sewage plants), namely, A. baylyi, A. bouvetii, A. grimontii, A. tjernbergiae, A. 
towneri, A. tandoii, and A. gerneri, increasing the actual number of validly described (genomic) 





Acinetobacters can be identified presumptively to the genus level as: Gram-negative, catalase-
positive, oxidase-negative, non-motile, non-fermenting, coccobacilli. They are short, plump, 
Gram-negative rods that are difficult to destain and may be misidentified as either Gram-
negative or Gram-positive cocci.   
 
Acinetobacter species of human origin grow well on solid media that are regularly used in 
clinical microbiology laboratories and hospitals, such as sheep blood agar or Tryptic Soy Agar, 
at 37°C. These organisms form smooth, sometimes mucoid, grey/white colonies. 
 
A. calcoaceticus-A. baumannii complex colonies resemble those of Enterobacteriaceae, with a 
diameter of 1.5 to 3 mm after overnight culture, whereas most of the other Acinetobacter species 
produce smaller and more translucent colonies. Unlike the Enterobacteriaceae, some 
Acinetobacter species outside the A. calcoaceticus-A. baumannii complex may not grow on 
McConkey agar (Peleg et al., 2008). 
 
Many methods have contributed to the better understanding of the clinical and epidemiological 
significance of Acinetobacter species during recent years, unfortunately, they are too laborious to 
be applied in daily diagnostic microbiology, and are used mainly in reference laboratories (Peleg 




More recent developments include the identification of A.baumannii by detection of the blaOXA-
51-like carbapenemase gene intrinsic to this species (Turton et al., 2006), and a simple PCR-based 
method described by Higgins et al. that exploits differences in their respective gyrB genes to 
rapidly differentiate between A. baumannii and Acinetobacter genomic species 13TU (Higgins et 
al., 2007). 
 
Species identification with manual and semi-automated commercial identification systems that 
are currently used in diagnostic microbiology, such as the API 20NE, VITEK-2, Phoenix, and 
MicroScan WalkAway systems, remain problematic (Bernards et al., 1995, Bernards et al., 1996, 
Hawley et al., 2007, Peleg et al., 2008). 
 
This can be explained in two main parts: the limited database content, and because the substrates 
used for bacterial species identification have not been customized specifically to identify 
acinetobacters.  Acinetobacter baumannii, Acinetobacter genomic species 3, and Acinetobacter 
genomic species 13TU are uniformly identified as A. baumannii by the most widely used 
identification systems (Peleg et al., 2008).  
 
The need for species identification of acinetobacters in routine clinical laboratories has been 
questioned by some researchers (Gerner-Smidt et al., 1991); however, from a clinical and 
infection control point of view, it is important to distinguish between the Acinetobacter 
baumannii group and Acinetobacters outside the A. baumannii group since the latter organisms 
rarely cause infection complications. Also, these organisms are usually sensitive to a wide range 
of antimicrobials, and infections caused by these organisms are usually benign. 
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However, from a research standpoint, clinical studies using appropriate and accurate methods for 
species identification of acinetobacters, including those within the A. baumannii group, are 
necessary to increase our knowledge of the pathogenicity, epidemiology, and clinical 





Members of the genus Acinetobacter are considered ubiquitous organisms;  acinetobacters can be 
recovered, after enrichment culture, from virtually all samples obtained from soil or surface 
water (Baumann, 1968). Similar studies have been carried to show that Acinetobacter baumannii 
is also ubiquitous in nature (Fournier and Richet, 2006).  
 
An epidemiological survey was performed to investigate the colonization of human skin and 
mucous membranes with Acinetobacter species, and showed that up to 43% of non-hospitalized 
individuals were colonized with these organisms (Seifert et al., 1997). An interesting study done 
in Hong Kong, by Chu et al. who found 53% of medical students and new nurses to be colonized 
with acinetobacters in summer versus 32% in winter (Chu et al., 1999). The seasonal variability 
in skin colonization could be attributed to the seasonal variation seen in clinical samples of 




As these two studies show, the chances of growth and survival of Acinetobacter baumannii in 
warm environments, such as Kuwait, are higher, and could therefore help explain the increased 
reports of Acinetobacter baumannii in warm climate regions such as the middle-east. 
 
  
1.5.Antimicrobials Agents and Acinetobacter 
 
There is great concern regarding the rise in the number of infections caused by Acinetobacter 
baumannii, especially since over the recent years many difficulties are being faced in 
administrating effective antimicrobial treatment.  The inherent properties of Acinetobacter 
baumannii, such as chromosomally encoded β-lactamases, as well as an effective permeability 
barrier (Peleg et al., 2008)., coupled with the ability to acquire and maintain resistance 
determinants on their mobile genetic elements, have rigorously decreased the number of 
effective antibiotics that can be used against the bacterial infections, and in some cases it was 
completely ineffective (Valencia et al., 2009).  
 
Due to these characteristics, there has been a gradual elimination of the effectiveness of the 
aminoglycosides, cephalosporins, penicillins, tetracyclines, and quinolones as treatment options 
for many infections of Acinetobacter baumannii. Consequently, we are left with carbapenems as 
the only sustainable group of antibiotics that may currently be successfully used to treat 
infections of Acinetobacter baumannii; mainly due to their low toxicity and good activity. 
Carbapenems are a subgroup of the β-lactam antibiotics and have the broadest spectrum of 
activity within this group (Peleg et al., 2008).  
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Imipenem was the first carbapenem to be approved for use, in 1985; which was a stable 
derivative of thienamycin, the antibiotic discovered in the 1970s and produced by Streptomyces 
cattleya. About twenty years later it was followed by meropenem – 1993 and more latterly by 
ertapenem - 2001, and doripenem - 2007 (Livermore, 2009).  
 
 
1.6.Classes of Antimicrobial Agents  
 
β-lactams: Each class of antibiotics differs from the others in their mode of action. The mode of 
action of β-lactam antibiotics is by inhibiting cell wall development in the bacteria. This is done 
by de-activating enzymes, which are located in the bacterial cell membrane during the 3
rd
 stage 
of manufacturing the peptidoglycan in cell wall synthesis. This acts as the main stress-bearing 
layer of the bacterial cell wall.  Once the peptidoglycan is no longer created, the bacterial cell 
wall is usually destroyed, which ultimately leads an inability to maintain the osmotic pressure 
leading to the destruction of the bacterial cell as a whole. 
 
These β-lactams do not inhibit a single enzyme, but a family of related enzymes. These penicillin 
binding proteins, four to eight in different bacteria, are all involved in different steps in the final 
stages of cell wall synthesis (Spratt and Cromie, 1988). 
 
Protein synthesis inhibitors: Macrolides, chloramphenicol, clindamycin, aminoglycosides, 
tetracyclines and oxazolidinones are other class of antibiotics. These mainly act by inhibiting 
bacterial growth by interfering with protein synthesis (Pestka, 1971). By and large, protein 
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synthesis inhibitors have little effect on infections caused by Acinetobacter spp, largely by their 
inability to penetrate the cell wall. 
 
DNA gyrase inhibition is another form of bacterial inhibition, found mainly by quinolones. Once 
the antibiotic blocks DNA synthesis and prevents the supercoiling of the DNA, the bacterial cell 
ceases to reproduce (Smith, 1986). Although used initially against A. baumannii, there efficacy 
has reduced they are no longer used (Peleg et al., 2008).  
 
RNA and folate inhibitors: Action of antibiotics in the rifampicin group act to inhibit DNA-
directed RNA polymerase. Once this is done, the bacterial cell can no longer create proteins and 
is ultimately inhibited (Wehrli et al., 1968). 
 
Some synergistic combinations have also been used, most notably the combination of 
trimethoprim and sulphonamides, which both act on the synthesis of tetrahydrofolic acid. The 
value of this combination over trimethoprim alone is yet to be proven (Coates et al., 2002). The 
difficulty that these compounds have in penetrating A. baumannii has ensured that they have not 
been used extensively against it. 
 
Carbapenems: Carbapenems are also β-lactam antibiotics. They were originally developed from 
thienamycin, a naturally-derived product of Streptomyces cattleya (Birnbaum et al., 1985). 
Imipenem and meropenem have the broadest spectrum of activity, they can act on both aerobic 
and anaerobic bacteria, with a high success rate, and therefore these β-lactams have become the 
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antibiotics of choice for the treatment of many bacterial infections, especially multidrug resistant 
Acinetobacter baumannii (MDR-AB) (Livermore and Woodford, 2006). 
 
There are 4 main differences between penicillins and carbapenems: 
1. Carbapenems have a carbon atom instead of sulphur in the five-membered ring. 
2. This ring is unsaturated in the carbapenems. 
3. The orientation of the hydrogen atoms on the rings differ in the two structures. 
4. The main side chain in the penicillin is at position 6 whereas it may be on the 
membered ring in the carbapenems (Figure.1) 
 
These differences mean that the shape of carbapenem significantly differs from that of penicillin, 
thus making it much more stable to β-lactamases. 
 
The structures of carbapenems are similar to that of penicillins, the main difference being that the 
sulphur atom in position 1 of the structure is been replaced with a carbon atom, hence the name, 
carba-penems (Kumagai et al., 2002). 
 
Carbapenems are able to retain activity against Gram-negative bacteria, even when they have 
become resistant to other β-lactam antibiotics such as the cephalosporins. In Gram-negative 
bacteria this has largely resulted from the emergence of the extended spectrum β-lactamases 
(ESBLs) or those which hyperproduce the AmpC-type cephalosporinase (Livermore, 1995). 





Figure 1. Showing the general structure of Carbapenems 
 
 
1.7.Carbapenem resistance in Acinetobacter baumannii 
 
There has been a worldwide recognition of the increase in carbapenem resistance among 
Acinetobacter baumannii. This represents an important event, particularly as the more resistant 
the bacteria evolve into, the harder it will be to treat and cure patients infected with them (Coelho 
et al., 2004). 
 
This class of antibiotics includes: imipenem, meropenem, doripenem, ertapenem, and 
razupenem. They are parenteral synthetic β-lactams that are derived from thienamycin, an 
antibiotic produced by Streptomyces cattleya (Livermore, 2009). 
 
There are two intrinsic enzymes, AmpC-type and OXA-51, which are considered as the most 
important types of β-lactamases, in almost all Acinetobacter baumannii isolates. The expression 
of the Amp-C type cephalosporinase at the basal level does not decrease the sufficiency of the 
expanded spectrum cephalosporins (Bou et al., 2000).  
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Additionally, insertion sequence ISAba1 which are present upstream of bla Amp-C gene 





Figure 2. A Summary of the distribution and genetic context of the OXA-type  enzymes in 
Acinetobacter baumannii. Each arrow and corresponding percentages correspond to the 
degrees  of amino  acid  homology  between  the  enzyme  clusters.  The  enzyme  clusters  
within large  circles signify the acquired  enzyme types, in contrast  to the naturally occurring  
OXA-51 cluster within the large square. (taken from Peleg et al., 2008) 
 
A summary of OXA-type enzymes in A. baumannii is shown in Figure 2. 
The first identified OXA-type enzyme with carbapenem-hydrolyzing activity was from a clinical 
A. baumannii strain isolated in 1985 from Edinburgh, Scotland (Paton et al., 1993). 
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1.8.Acquisition of oxacillinases (class D enzymes)  
 
To date, over 227 different variants of class D OXA-type β-lactamases have been investigated on 
the protein level (Genebank, 2011).  
 
The oxacillinase groups are unique β-lactamases and mainly occur in Gram-negative bacteria. 
Initially, they were thought to be plasmid-mediated only but since the identification of the OXA-
51 β-lactamase gene, located on the chromosome of an A. baumannii strain from Argentina 
(Brown et al., 2005), the source of these plasmid enzymes has now been identified. 
 
Oxacillinases commonly hydrolyze oxacillin faster than classical penicillins such as benzyl 
penicillin,  yet, the efficiency of hydrolytic class D β-lactamases (CHDLs) against carbapenems 
is very low, up to 1000-fold compared with MBLs (Poirel and Nordmann, 2006b). 
 
The first report of imipenem resistant Acinetobacter baumannii was reported in 1993 (Urban et 
al., 1993). At around the same time, the discovery of the first novel group of narrow spectrum 
OXA-type β-lactamases was made. The enzyme, which was called OXA-23, was found to have 
carbapenem hydrolysing activity, although the strain was obtained before the use of imipenem in 









The OXA-type carbapenem hydrolysing class D β-lactamases in Acinetobacter baumannii are 
classified into four subgroups: OXA-23-like, OXA-40-like, OXA-51-like and OXA-58-like 
(Brown and Amyes, 2006). Also note that, the third sub group of OXA-51-like is intrinsic and 
naturally located in all Acinetobacter baumannii (Heritier et al., 2005). 
 
1.9.1. OXA-23 Group 
 
The first family is OXA-23, formerly named ARI-1, and was identified in 1995 in Scotland and 
afterwards renamed to OXA-23, due to its genetic characterization. The OXA-23 group also 
includes OXA-27 and OXA-49. The first identification of OXA-27 was made in Singapore, 
while OXA-49 was in China; both of them were identified from single carbapenem resistant 
Acinetobacter baumannii strains rather than outbreaks (Turton et al., 2005). OXA-23 was 
identified a few years later, in Acinetobacter baumannii isolates in Brazil (Dalla-Costa et al., 
2003), China (Yu et al., 2004) and Singapore (Coelho et al., 2004). See (Figure 3) 
 
1.9.2. OXA-40 Group 
 
The second family is the OXA-40, which was identified in Spain, from a highly carbapenem-
resistant Acinetobacter baumannii strain sharing 63% & 60% amino acid identity with OXA-
51/69 and OXA-23 respectively (Bou et al., 2000). This group also includes the variants OXA-
24, OXA-25, OXA-26, and OXA-72.  These variants of OXA-25, OXA-26 and OXA-40 were 
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identified in strains from Portugal, Spain, and Belgium afterwards. (Afzal-Shah et al., 2001), 
while the OXA-72 Acinetobacter baumannii strains were identified in Thailand (Walther-
Rasmussen and Hoiby, 2006). (See Figure. 3) 
 
1.9.3. OXA-51 Group 
 
The third family was first identified by Brown et al. (2005) from a strain isolated in Argentina. 
This enzyme, which was called OXA-51, was characterized from two clones of Acinetobacter 
baumannii. OXA-51 shared a 63% amino acid identity with subgroups 1 and 2. Other members 
of the OXA-51 enzyme group were soon found around the world; they were found in 
carbapenem resistant strains and each enzyme shared 98% to 99% identity with OXA-51 (Brown 
and Amyes, 2006).  
 
The identifications of these variants were based on the OXA-51-like enzyme and the 
construction of this group revealed three clusters of OXA-66, OXA-69 and OXA-98 of closely 
related enzymes. (See Figure. 3) 
 
1.9.4. OXA-58 Group 
 
The fourth family has only one member, OXA-58, where the first identification of OXA-58 was 
made in France in 2003. It has also been isolated from strains in Argentina, Kuwait and southern 
England (Coelho et al., 2004). OXA-58 has the ability to hydrolyze penicillins and Imipenem 
significantly and, furthermore, OXA-58 is also active against the majority of cephalosporins 
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(Poirel et al., 2005). OXA-58 has a low percentage of amino acid identity compared with the 
other oxacillinases, (48 and 47%) amino acid identity with OXA-23 and OXA-40, respectively, 

























































































































































































































Figure 3. Modified OXA-51-like linkage map showing all related OXAs. (modified from Evans 





1.10. Clinical Laboratory Detection of Carbapenemases 
 
A variety of β-lactamases produced by Acinetobacter baumannii are capable of hydrolyzing 
carbapenems (Queenan and Bush, 2007). 
 
Phenotypic tests for evaluating the presence of serine carbapenemases (OXA-type) in 
Acinetobacter baumannii have not yet been described. The most frequently used methods for 
detecting MBLs have been disk approximation methods comprising meropenem (Figure. 4) and 
imipenem (Figure. 5) plus EDTA (Gales et al., 2003).  
 
            







1.11. Natural Habitat of Acinetobacter  
 
The majority of Acinetobacter species generally can be found and isolated from environmental 
samples, mainly in the soil, or from non-clinical human samples such as skin. There are many 
members of the genus which are usually considered to be environmental organisms (Peleg et al., 
2008).  A study of water and soil samples from California, 28 of 30 soil samples and 29 of 30 
water samples were culture-positive for Acinetobacter spp. (Baumann, 1968). The microbial 
communities from the extreme environments of six Andean lakes were studied, five different 
Acinetobacter isolates were identified, one of which was determined to be Acinetobacter 
johnsonii (Ordonez et al., 2009). 
 
Acinetobacter calcoaceticus isolates have been discovered in the soil surrounding plant roots. 
Their symbiotic relationship was shown to, which promoted plant growth in vitro (Peix et al., 
2009). Another species: Acinetobacter baylyi, which was also isolated from the soil, was shown 
to be able to acquire plant DNA material through horizontal gene transfer (Pontiroli et al., 2009). 
An isolate of Acinetobacter baumannii, recovered from oil-contaminated desert soil in Kuwait, 
and was shown to be an oil degrading bacterium (Obuekwe et al., 2009). 
 
In a series of studies that examined the association of Acinetobacter spp. with humans, a wide 
range of results were found. The study of skin carriage from 192 healthy humans in London, UK, 
an Acinetobacter carriage rate of 44% was discovered, Acinetobacter genospecies 15BJ 
accounted for 12.5%, with Acinetobacter lwoffii accounted for 61% of the isolates and 
Acinetobacter radioresistens accounted for 8% (Berlau et al., 1999). Similar research was done 
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in Cologne, Germany, where it was found that 40 healthy people had an Acinetobacter spp 
carriage rate of 42.5%, with 58% of isolates accounted for by Acinetobacter lwoffii, 20% by 
Acinetobacter johnsonii, and 10% by Acinetobacter junii (Seifert et al., 1997).  Similarly, a study 
of skin carriage by medical students and nurse students in Hong Kong found the Acinetobacter 
carriage rate to be 37.8%, but Acinetobacter genospecies 3 was the most widespread accounting 
for 32% of isolates, while Acinetobacter genospecies 13TU the second most common,  
accounting for around 12% (Chu et al., 1999). It is probable that the difference in the skin flora 
observed in the study from Hong Kong may be due to the study group being in contact with 
hospitalized patients, where carriage of Acinetobacter species 3 and 13TU is more widespread. 
While it is apparent that the environment of many of the members of the genus Acinetobacter is 
either aquatic or soil, there is dispute as to the natural habitat of a few of its species: 
Acinetobacter baumannii, Acinetobacter genospecies 13TU, and also Acinetobacter genospecies 
3 - which are not usually found in environmental samples, but predominantly in hospital 
environments and clinical samples. 
 
 
1.12. Acinetobacter baumannii in the Middle East 
 
There have been numerous outbreaks of multidrug-resistant Acinetobacter baumannii reported in 
Middle Eastern hospitals, namely in Kuwait, Iraq, Iran, Israel, Egypt, Bahrain, Qatar, Saudi 
Arabia, and the United Arab Emirates. All have documented a variety of carbapenemases, with 




The map in figure 6 below shows the countries in the Middle East that have reported outbreaks 




Figure 6. Countries in the Middle East underlined in red are ones that have reported outbreaks of 














1.13. Community-Acquired Acinetobacter Infections 
 
Some of the members of the Acinetobacter genus have emerged to prominence relatively 
recently, mainly due to the increasing number of human infections for which they are 
responsible. Many members of the Acinetobacter genus have been identified as the cause of 
infections, nevertheless, there are three species that are implicated in causing infections far more 
frequently. These species are Acinetobacter baumannii, Acinetobacter genospecies 3 (more 
recently called Acinetobacter pittii) and Acinetobacter genospecies 13TU more recently called 
Acinetobacter nosocomialis).  
 
The infections from Acinetobacter baumannii are of a particular problem, since they can be very 
difficult to treat.  In general, Acinetobacter species are opportunistic pathogens, and usually only 
cause infections in people of whom are immunocompromised, or suffer from other immune 
debilitating diseases from a previous underlying condition (Falagas et al., 2007). 
 
Reports of infections by Acinetobacter species in the community have been reported, even 
though very infrequently. Upon reviewing these reports, it was discovered that in the great 
majority of community cases, patients were diagnosed with pneumonia; while the remaining 
cases were diagnosed as bacteraemia infections.  
 
The majority of patients were found to have severe conditions such as: chronic obstructive 
pulmonary disease, diabetes mellitus, renal disease. Smokers and excessive alcohol consumers 
were also amongst those patients. The infections were just about all reported to be caused by 
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Acinetobacter baumannii; however due to the difficulty in identifying the species within the 
genus, particularly between members of the Acinetobacter baumannii -Acinetobacter 
calcoaceticus complex, it may be possible that other species were also involved. 
 
The mortality associated with infections was very high, at 56%, though this is possible to be an 
over-estimation, since many mild cases of Acinetobacter infections would not normally be 
reported. Also, the bulk of the reports originated from areas with climates that are tropical and 
subtropical. Whether these resulting conditions in the reports were due to climatic or social 
factors, it’s still not clear (Falagas et al., 2007). 
 
 
1.14. Hospital-Acquired Acinetobacter Infections 
 
Whilst community-acquired Acinetobacter infections are infrequent, hospital-acquired infections 
are far more common, and of a far bigger concern. Infections are associated with 
immunocompromised patients, with infection rates regularly being in their highest in intensive 
care units (ICUs) and in surgical wards. The organism that typically causes pneumonia 
associated with the mechanical ventilators, and also bloodstream infections, following invasive 
procedures (Peleg et al., 2006). 
 
Acinetobacter baumannii, Acinetobacter pittii and Acinetobacter nosocomialis are the three 
species which are mostly frequently implicated in cases of hospital-acquired infection. 
Epidemiological surveys have typically identified Acinetobacter baumannii to be, by far, the 
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most frequent causative organism of infections, although there reports of higher rates of isolation 
of Acinetobacter pittii have been made (Boo et al., 2009, Lim et al., 2007, Chen et al., 2007).  
 
Acinetobacter pittii and nosocomialis have a propensity of sporadically causing infections. 
Fortunately, they are relatively susceptible to antimicrobials. On the other hand, the same cannot 
be said of Acinetobacter baumannii. The mortality rates for Acinetobacter species other than 
Acinetobacter baumannii have been found to be very low, between 7% and 18% respectively 
(Choi et al., 2006, Seifert et al., 1994b).  
 
Conversely, the mortality rates of patients infected with Acinetobacter baumannii has been 
reported as being between 8% and 43% (Falagas et al., 2006).  Furthermore, the duration of stay 
in the hospital in association with Acinetbacter baumannii infections was considerably longer 
than that for other Acinetobacter species (Choi et al., 2006).  
 
Acinetobacter baumannii outbreaks are often clonal, and the spread of clones or lineages can be 
seen both nationally and internationally. A great number of global infections can be attributed to 
three of these epidemic lineages, that have been termed European clones I, II and III (Van Dessel 
et al., 2004, Dijkshoorn et al., 2007).  
 
There is an continuing infection control problem in the UK, which is related to the circulation of 
several clonal lineages of Acinetobacter baumannii, termed the South-East clone (SE clone), 
OXA-23 clone I and OXA-23 clone II (Coelho et al., 2006).  
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It is still unclear what the reasons are that make some lineages of Acinetobacter baumannii 
particularly successful, and allows them to spread internationally; certainly part of the answer is 
likely to be because of the rather high level of antimicrobial resistance shown in this bacteria, 
and also by its ability to acquire and maintain resistance determinants.  It is for the reasons 
previously mentioned that of all of the species belonging to the Acinetobacter genus; it is 
Acinetobacter baumannii that is the organism that gives us the greatest cause for concern.  
 
1.14.1. Acinetobacter Pneumonia  
 
In most cases, the majority of A. baumannii isolates are from the respiratory tracts of 
hospitalized patients. In most circumstances it is difficult to distinguish between the upper 
airway colonization and true pneumonia.  There is no doubt, however, that true ventilator-
associated pneumonia (VAP) due to A. baumannii occurs (Peleg et al., 2008). 
Community-acquired pneumonia due to A. baumannii has been described from tropical regions 
of Asia (Peleg et al., 2008).  Most typically, the disease occurs during the rainy season among 
people with a history of alcohol abuse, and some cases may sometimes require admission to an 
ICU (Anstey et al., 2002). 
 
1.14.2. Bloodstream Infections 
 
In a large study of nosocomial bloodstream infection in the United States (1995–2002), A. 
baumannii was the 10th most common aetiologic agent, being responsible for 1.3% of all 
monomicrobial nosocomial bloodstream infections (0.6 bloodstream infection per 10,000 
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admissions) (Wisplinghoff et al., 2004). A. baumannii was a more common cause of ICU-
acquired bloodstream infection than of non-ICU-ward infection. 
 
One hundred and two patients had bloodstream infections at sites treating U.S. military members 
injured in Iraq or Afghanistan from 1 January 2002 and 31 August 2004 (CDC, 2004).  
 
1.15. Traumatic Battlefield and Other Wounds 
 
Acinetobacter baumannii is frequently isolated from wounds of combat casualties from Iraq or 
Afghanistan (Yun et al., 2006).  These reports could prove valuable as they suggest the 
possibility of a link between desert locations in the Middle East, and the prevalence of 
Acinetobacter baumannii infections, since dust storms are a natural phenomenon there, as well as 
top soil layers that are displaced and dispersed via tanks and helicopters, that could easily reach 
flesh wounds and increase the chances of infection to wounded individuals. 
 
1.16. Treatment of Acinetobacter baumannii infections 
 
The treatments available for bacteria that are innately resistant to many classes of antibiotics are 
decreasing. The dependability of effective treatment for Acinetobacter infections has become 
very restricted (Pieroni, 1997). On the other hand, carbapenems such as: imipenem and 




Non-rational use of carbapenems used in treating patients has caused an increase in the overall 
resistance of Acinetobacter baumannii to this group of antibiotics (Livermore and Woodford, 
2000). Nevertheless, if used prudently, then their efficacy could be ensured for a longer time 
(Gales et al., 2001). 
 
Colistin is another option; which seems to be relatively secure and effective for the treatment of 
patients with infections caused by multi-drug resistant Acinetobacter baumannii (Kroeger et al., 
2007, Pantopoulou et al., 2007). Tigecycline has also been tested and successfully used as 
treatment against Acinetobacter baumannii infections (Al-Sweih et al., 2009).  Occasionally, 
aminoglycosides could also be used in combination with an effective β-lactamase with 
fluoroquinolone or rifampin (Bergogne-Berezin and Towner, 1996).  In general, carbapenems, 
colistin, minocycline and tigecycline remain the best and only solutions against Acinetobacter 
infections. 
 
Prevention, as the saying goes, is the best medicine. This type of precautionary approach would 
readily help decrease the chances of infection in hospital wards. Washing hands is one of the 
most important methods for preventing infection, where 30% of nosocomial infection could be 








1.17. Typing methods for Acinetobacter baumannii 
 
Typing of Acinetobacter is of great importance for distinguishing the sources and modes of 
spreading for these bacteria. Typing is even of greater importance during an outbreak, because it 
is used to determine if the organism responsible is a clone or an unrelated strain, as well as 
revealing the source of the outbreak (Towner et al., 1991).  
 
In 1987, the earliest attempts to type Acinetobacter spp were performed. They were based on 
biotypes and antibiotypes (Bouvet and Grimont, 1987). Since then, several biotyping systems 
have been applied to type Acinetobacter spp. One of the systems relied upon biochemical 
profiles; with all the results scored as either positive or negative, and then were used to compare 
strain types. 
 
Another bio-typing technique consisted of five active tests for dividing A. baumannii isolates 
into 19 biotypes. This method was used to type the related genomic species 3 and 
13TU (Bouvet et al., 1990). However these often prove unreliable. 
 
1.18. Pulsed-Field Gel Electrophoresis 
 
Even in the face of sequence-based methods that are now readily available and are 
challenging PFGE as the gold standard for typing of many bacterial species, for 
Acinetobacter, PFGE still remains the reference method of choice. It is a relatively 
laborious method, which requires several days before generating a typing result, but the 
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required equipment is now standard not only in most reference laboratories but also in 
hospital- based microbiology laboratories. Basically, Pulsed Field Gel Electrophoresis 
(PFGE) is restriction analysis, which is generated from intact chromosomal DNA, to compare 
the fingerprints of different strains following digestion with endonucleases; such as the Apa1 
enzyme (Seifert et al., 1994a). Usually, the restriction endonuclease ApaI is used to restrict 
the intact chromosomal DNA of the Acinetobacter baumannii isolates (Bou et al., 2000). 
 
PFGE is costly, and requires a lot of equipment, taking several days to prepare the DNA and 
subsequently digests it with the endonuclease. The process is easy to handle, readable, replicable, 
and provides highly discriminatory results which give useful epidemiological information 
(Gouby et al.,1992).The resulting chromosomal fragments are separated by electrophoresis, and 
fingerprint profiles are compared visually or using specialized computer programs that also allow 
the storage of profiles in a database.  
 
As with other comparative typing systems that are based mainly on a side-by-side comparison of 
molecular fingerprint patterns of a limited number of strains, comparisons between different 
laboratories have been a problem with PFGE, but recent studies show that with adequate 
standardization of protocols, inter-laboratory reproducibility can be achieved (Seifert et al., 
2005). 
This approach would permit the recognition of epidemic strains and the early detection of multi-
hospital or nationwide outbreaks, particularly if cases are geographically separated. Nowadays, 
there are other methods, such as MLST, that are found to be optimal for large scale typing 
(Seifert et al., 2005). 
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1.19. Aims of the thesis 
 
The main objectives of this study were to: 
 Compare the validity of phenotypic identification of Acinetobacter baumannii. 
 Study the infiltration of carbapenem resistance into A. baumannii in Kuwait. 
 To investigate the clonal relationship between multi-resistant A. baumannii strains 
isolated in Kuwait. 

















2. Materials and Methods 
 
2.1. Strain collection  
 
A total of 120 clinical bacterial isolates were collected from the Mubarak Al-Kabeer Hospital in 
Kuwait - during a period of 2 years - from 2006 to 2008. Several outbreaks occurred during those 
years and samples were collected accordingly. The sources were mainly from blood, urine, pus 
swab, endotracheal, rectal swab, and skin. The non-repeated samples were collected from a 
variety of patients of differences in age, sex, and nationality. All isolates collected were cultured 
and stored in both long term and short term methods (see below).  Once all the samples were 
collected, they were shipped to the UK and stored at the University of Edinburgh, where further 
research and tests were carried. 
 
2.2.Short Term Storage 
 
Short term storage method is mainly used for working with the isolates on a weekly basis, and in 
this form it was possible to ship them to the UK with minimal loss to the viability of the bacterial 
isolates. The isolates were sub-cultured on MacConkey agar (Oxoid, Basingstoke) and then 
incubated at 37 °C for a period of 24 hours. The next day, a single colony was taken using a 
sterile loop and inoculated into IST broth, which was put in an orbital shaker and allowed to 
grow over night at 37°C. With the help of a pipette, 900μL of the overnight culture was added to 




2.3.Long Term Storage 
 
The method used for storing the isolates, long-term, was the Cryobank System Beads (Kalyx 
Biosciences Inc, Orlando, USA). This was done by taking a single freshly grown colony, which 
was grown overnight at 37°C, on MacConkey agar and added to the Cryobank System vial. The 
vials contained a collection of beads that secured the bacterial strains for storage. This is a very 
successful for long-term storage of bacterial isolates. In accordance to the manufacturer's 
instructions, all the strain containing vials were stored in a -80 °C freezer. When required the 
bacteria were removed by taking out a single bead without disturbing the rest. 
 
2.4.Media and Chemicals 
 
All the antibiotic agents used were purchased from the Sigma-Aldrich Company Ltd (Poole, UK) 
unless otherwise stated. All media were purchased, in powdered form, from Oxoid (Basingstoke, 
UK). The broths and agar plates were prepared according to the manufacturer’s instructions. 
They were sterilized at 121°C/15 psi for 15 minutes by autoclaving. Normal saline was prepared 
by dissolving 0.85 g of NaCl in 100mL of distilled water (D/W) and sterilized by autoclaving. 
 
 
2.4.1. 10X TAE buffer preparation: 
The preparation of 10X TAE buffer was comprised of: Trizma base (Sigma) (48.44g) of and 
3.72g of EDTA (Ethylene diamine tetra acetic acid) disodium salt dehydrate 99% were dissolved 
in D/W with the addition of 11.4 ml glacial acetic acid to give a final volume of one litre. The pH 
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was adjusted to 8.0 with 1M HCl and the solution was sterilized. For gel running, a dilution of 
1:10 was made to a final concentration of 1X and used for gel electrophoresis.  
 
 
2.4.2. 10X TBE buffer preparation: 
The preparation of 10X TBE Buffer was comprised of: Tris-base (108g) and 55g of boric acid 
were dissolved with 40mL of 20mM EDTA in one litre of D/W. The pH was adjusted to 8.0 with 
1M HCl and the solution was sterilized. 0.5X TBE buffer was also used for the running of PFGE 
gels.  


















2.5.1 VITEK-2 System 
 
All the isolates were screened and identified via the VITEK-2 System (BioMerieux, Marcy 
L'Etoile, France) in Kuwait, in accordance to the manufacturer’s instructions. This is a 
phenotypic type of identification which depends on biochemical reactions to identify the isolates. 
 
One hundred and twenty strains were inoculated onto MacConkey agar (Oxoid) plates and then 
incubated overnight at 37°C. A single isolated colony was used for identification by the 
phenotypic VITEK-2 Systems method, done according to the manufacturer’s instructions 





2.6.1. Polymerase chain reaction (PCR) 
 
PCR reagents: 
All PCR reagents were performed using Promega reagents (Promega, Southampton, UK), GoTaq 
Flexi DNA Polymerase (5u/μl) in 5x green or colourless buffer, MgCl2 solution (25mM) and 
deoxynucleoside triphosphates (dNTP) / PCR nucleotide mix (10mM each). Sterilized distilled 
water was used as the dilutents. 
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All PCR reactions unless otherwise indicated were performed in 50μl of 1.5mM (2μl) MgCl2, 
0.1mM (1μl) dNTPs, 1X reaction buffer (10μl), 0.05mM (0.5μl) each primer, 1μl template and 
0.2 units of Taq in sterilized distilled water.  
 
All the PCRs that were performed were done in a total volume of 50µL, with reagents supplied 
by Promega (Promega, Southampton, UK) according to the manufacturer’s guidelines. 
 
The primers that were used in this study were supplied by Eurofins MWG operon, UK. They 
were diluted to a concentration of 100pmol/µL as stock standards. 12.5pmol of primer 
concentration was used for each PCR reaction. PCR amplification of blaOXA51-like gene was 
carried out on all the samples, in accordance to the conditions set by Brown et al (2005). 
 
2.6.2. Extraction of DNA 
Following overnight sub-culture on MacConkey agar at 37
o
C, DNA extraction was performed by 
boiling 5 identical colonies in 50 µL of sterile distilled water for about 15-20 minutes in 










PCR Primer data: 
The primers used for the PCR reaction were to amplify the blaOXA-51-like gene. The primers OXA-
69 Forward and OXA-69 Reverse were used for the PCR. The primers and expected fragment 
size were: 
OXA-69F  F 5'-CTAATAATTGATCTACTCAAG-'3 
OXA-69R  R 5'-CCAGTGGATGGATGGATAGATTATC-'3 
 
The expected size was 975 base pairs. 
 
2.6.3. Gel electrophoresis and staining 
 
Agarose gels (1.5%) (Gensieve LE agarose, Flowgen, UK) were prepared in 1X TAE buffer and 
run at 100V for the preparations of plugs. 0.7% gels were prepared for the running of plasmid 
DNA and they were run at 60V for 19hrs for better resolution. All the gels were stained in a 100 
mL of gel red (Biotium, US) staining solution (50 μL gel red dissolved in 100ml of 0.1M NaCl) 
and visualized by the Gel Doc system. 
 
 
2.7.Pulsed-Field Gel Electrophoresis (PFGE) 
 
PFGE was performed on all isolates identified genotypically as Acinetobacter baumannii 
isolated from the Mubarak Al-Kabeer Hospital in Kuwait, in accordance to the procedure 
described by Seifert et al. (2005). The isolates were inoculated onto Iso-Sensitest (IST) agar 
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(Oxoid, Basingstoke) and incubated overnight at 37°C in ambient air. A loopful of bacteria was 
removed from the agar surface with a sterile plastic loop and suspended in a glass or polystyrene 
round bottomed tube containing 2.5 ml of cell suspension buffer (100 mM Tris, 100 mM EDTA, 
pH 8.0). Each cell suspension was adjusted to give a cell density of approximately 10
9
 cells/ml. 
This was performed by using the spectrophotometer. The pellet was resuspended by vortexing, 
and the cell suspension was incubated at 55°C for 10 min a water bath. An aliquot of 25 μL 
proteinase K (20-mg/ml stock solution in ultrapure water) was added, and the suspension was 
mixed gently by inverting the tube two to four times. An equal volume of melted 1% CHEF 
genomic agarose (Bio-Rad, UK)-1% sodium dodecyl sulphate (Fisher Scientific, UK) in TE 
buffer (10 mM Tris, 1 mM EDTA, pH 8.0) was added to the cell suspension, and the suspension 
was mixed gently by inverting the tube 10 to 12 times. The agarose-cell suspension mixture was 
immediately dispensed into the wells of reusable plug moulds. The agarose plugs were allowed 
to solidify at room temperature for 5 min and at 4°C for another 5 min. A single plug was then 
transferred to disposable screw-cap 50-ml polypropylene tubes containing 5 ml of cell lysis 
buffer (50 mM Tris, 50 mM EDTA [pH 8.0], 1% sarcosine) and 25 μL of proteinase K (20 
mg/ml stock solution). Lysis was performed at 55°C in a water bath for two hours with. After 
lysis, the buffer was carefully removed and the plugs were washed five times (15 min/wash) at 
55°C (two times with sterile ultrapure water and three times with TE buffer; 10 ml for each 
washing step) in a water bath. The water and TE buffer were preheated at 50 to 55°C before each 
washing step. After the last wash, the TE buffer was poured off and 10 ml of fresh TE buffer was 
added to each tube. If the plugs were not used on the same day then they were refrigerated. For 
the restriction of the genomic DNA a single slice of the plug (4.0 by 5.5 mm) was cut with a 
scalpel or razor blade and transferred to a microcentrifuge tube containing 200μL of the 
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restriction buffer with 30U ApaI (Promega, Southampton, UK). The plug slices were incubated 
at 37°C for 24 hours in a water bath. 1.0% gels were prepared in 0.5X TBE buffer for PFGE and 
the gels were run with the plugs in CHEF apparatus with an initial pulse 5 sec and final pulse 25 
sec,  200V  for 20 hours at 14°C . The gel was stained with gel red on the completion of run. 
Cluster analysis was performed by the unweighted pair group method with mathematical 
averaging (UPGMA), and DNA relatedness was calculated by using the band-based Dice 
coefficient with a tolerance setting of 1.5% band tolerance and 1.5% optimization setting for the 
whole profile. Gel analysis was performed using the BioNumerics v4.0 software (Applied Maths, 
Sint-Martins-Latem, Belgium). A value of 75-80% was chosen as the threshold for the 
establishment of clonal relatedness of the unknown isolates. The banding patterns were also 
interpreted according to the criteria suggested by Tenover et al. (1995). 
 
2.8.Minimum Inhibitory Concentration Test 
The isolates were tested for their susceptibility to the two major carbapenems: imipenem (IPM) 
(Merck, Sharp & Dohme Ltd, Hertfordshire, UK) and meropenem (MEM) (AstraZeneca, 
Cheshire, UK). 
After overnight culturing on MacConkey agar, a single colony was suspended using a sterile 
loop in 5 mL of Iso-sensitest broth (Oxoid, Basingstoke) and grown overnight at 37°C/180 rpm 
in an orbital shaker. The minimum inhibitory concentrations (MICs) were determined by the agar 
double dilution technique in Iso-sensitest agar in accordance specification of the British Society 
for Antimicrobial Chemotherapy (BSAC) methodology (British Society for Antimicrobial 
Chemotherapy, Version 10.2, 2011). The results were interpreted according to the BSAC 
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guidelines. Pseudomonas aeruginosa NCTC 10662, Escherichia coli NCTC 10418 and 
Staphylococcus aureus NCTC 6571 were used as control strains. 
 
 
2.9.Sequencing of PCR products 
 
The amplification of the PCR products were purified using a PCR cleanup kit (Qiagen, West 
Sussex, UK) and an ABI3730 capillary sequencer (Applied Biosystems, Warrington, UK). OXA-
69 products were used for the complete sequencing map of the Acinetobacter baumannii 
samples. The DNA sequences were then analyzed using the Chromas, Multalin, EXPASY and 
BLAST software. Eventually, the sequences were compared to the published sequences of A. 
baumannii using an online search facility (http://www.ncbi.nih.gov/BLAST). The amino acid 























The first stage of the experiment was to validate the phenotypes of the bacterial isolates, both 
phenotypically and genotypically. The first phase was to identify them phenotypically using the 
VITEK-2 system. Only the positive isolates were then subjected to a genotypic type of 
identification, using PCR (Polymerase Chain Reaction) of OXA-69 primer that exhibits bands at 
975bp, which are used to verify and solidify the results. Once the identification was completed, 
the samples were sequenced. The resulting sequences were then run through BLAST (Basic 
Local Alignment Search Tool) on the PubMed website http://blast.ncbi.nlm.nih.gov/.  
 
All the sequence results were then recorded and tabulated in the results below. Typing of the 
isolates was performed to identify the clonality and relatedness in all of them, this was done by 
the PFGE (Pulsed-Field Gel Electrophoresis) method, and the resulting dendogram was enlisted 
in the results below. 
 
 
3.1. Phenotypic Identification  
3.1.1. VITEK-2 System  
 
The Vitek-2 System (BioMerieux, Marcy L'Etoile, France) is a phenotypic system of 
identification, which depends on the biochemical reactions between the bacterial isolates 
suspended in their respective tubes of solution, and the media in the VITEK-2 Identification 




In the first stage of the experiment, 120 sample isolates were inoculated onto MacConky agar 
(Oxoid) plates and then incubated overnight at 37°C. A single colony was then taken and 
suspended into solution. The turbidity of the bacterial suspension was adjusted with VITEK 
Densichek (bioMerieux) to match the McFarland 0.5 standard in 0.45% sodium chloride. Then 
the VITEK 2 ID-GN (Gram Negative) card and the bacterial suspension tubes were manually 
loaded into the VITEK-2 system. Following steps on the software were done according to the 
manufacturer’s instructions (BioMerieux, Marcy L'Etoile, France). 
 
Of the 120 samples, 110 were identified as Acinetobacter baumannii positive by the VITEK-2 
system. The results are recorded below on Table 1. 
 
The Date, Sex, and Source of each positive sample were also recorded on Table 1. 
 





Date Sex Source A. baumannii 
Detection 
1 2006 M Rectal Swab +ve 
2 2006 M ICU +ve 
3 2006 M Rectal Swab +ve 
4 2006 F Endotracheal +ve 
5 2006 M Urine +ve 
6 2006 M Tip +ve 
7 2006 M Urine +ve 
8 2006 F Urine +ve 
9 2006 F Blood +ve 
10 2006 M Blood +ve 
11 2006 M Blood +ve 
12 2006 M Tip +ve 
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13 2006 M Blood +ve 
14 2006 M Blood +ve 
15 2006 M Blood +ve 
16 2006 M Urine +ve 
17 2006 F ICU +ve 
18 2006 F Blood +ve 
19 2006 M Blood +ve 
20 2006 M Endotracheal +ve 
21 2006 F Blood +ve 
22 2006 M Blood +ve 
23 2006 F Tip +ve 
24 2006 F Tip +ve 
25 2006 M Pus Swab +ve 
26 2006 M Tissue +ve 
27 2007 M Tissue +ve 
28 2007 F Urine +ve 
29 2007 F Rectal Swab +ve 
30 2007 F Tip +ve 
31 2007 M Blood +ve 
32 2007 M Blood +ve 
33 2007 M Blood +ve 
34 2007 M Blood +ve 
35 2007 M Skin Swab +ve 
36 2007 M Blood +ve 
37 2007 M Blood +ve 
38 2007 F Blood +ve 
39 2007 F Endotracheal +ve 
40 2007 M Endotracheal +ve 
41 2007 F Endotracheal +ve 
42 2007 F Endotracheal +ve 
43 2007 M Urine +ve 
44 2007 F Pus Swab +ve 
45 2007 M Endotracheal +ve 
46 2007 F Endotracheal +ve 
47 2007 M Sputum +ve 
48 2007 M Blood +ve 
49 2007 M Blood +ve 
50 2007 M Aspiration 
Fluid 
+ve 
51 2007 M Rectal Swab +ve 
52 2007 M Pus Swab +ve 
53 2007 F Pus Swab +ve 
54 2007 F Pus Swab +ve 
55 2008 M Blood +ve 
56 2008 M Endotracheal +ve 
57 2008 M Blood +ve 
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58 2008 F Blood +ve 
59 2008 F Blood +ve 
60 2008 M Urine +ve 
61 2008 M Blood +ve 
62 2008 F Blood +ve 
63 2008 M Tip +ve 
64 2008 M Blood +ve 
65 2008 F Endotracheal +ve 
66 2008 F Pertonial  +ve 
67 2008 F Rectal Swab +ve 
68 2008 M Blood +ve 
69 2008 M Urine +ve 
70 2008 F Pus Swab +ve 
71 2008 F Blood +ve 
72 2008 M Endotracheal +ve 
73 2008 M Tissue +ve 
74 2008 M Pus Swab +ve 
75 2008 M Blood +ve 
76 2008 F Tip +ve 
77 2008 M Tip +ve 
78 2008 M Endotracheal +ve 
79 2008 F Urine +ve 
80 2008 F Blood +ve 
81 2008 F Endotracheal +ve 
82 2008 F Blood +ve 
83 2008 F Blood +ve 
84 2008 F Blood +ve 
85 2008 F Endotracheal +ve 
86 2008 F Tip +ve 
87 2008 F Aspiration 
Fluid 
+ve 
88 2008 F Blood +ve 
89 2008 M Stool +ve 
90 2008 F Urine +ve 
91 2008 F Blood +ve 
92 2008 F Stool +ve 
93 2008 F Urine +ve 
94 2008 F Urine +ve 
95 2008 M Blood +ve 
96 2008 F Stool +ve 
97 2008 F Urine +ve 
98 2008 F Blood +ve 
99 2008 F Blood +ve 
100 2008 M Urine +ve 
101 2008 F Urine +ve 
102 2008 F Blood +ve 
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103 2008 F Sputum +ve 
104 2008 M Blood +ve 
105 2008 M Urine +ve 
106 2008 F Blood +ve 
107 2008 F Sputum +ve 
108 2008 F Tip +ve 
109 2008 M Sputum +ve 
110 2008 F Blood +ve 
 
According to Table 1. The statistics that can be derived from the samples, which were analyzed 
via VITEK-2, are as follows: 
 
Percentage of Female patients with positive Acinetobacter baumannii = 49.1% 
Percentage of Male patients with positive Acinetobacter baumannii = 50.9% 
 
The number of positive samples for each year was also calculated and presented in a bar chart 
below in figure 7.  The data is as follows: 
 
Total number of positive samples for the year 2006 = 26 (18 males, 8 females) 
Total number of positive samples for the year 2007 = 28 (17 males, 11 females) 




Figure 7. Bar Chart Showing the number of positive samples isolated from Mubarak Al-Kabeer 
Hospital during the years 2006, 2007, 2008. 
 
According to figure 7 we could clearly observe a significant increase in the number of females 
that tested positive for Acinetobacter baumannii infection according to the VITEK-2 system in 











Figure 8. Bar Chart showing the total number of male and female samples isolated and their 
respective sources identified by VITEK-2 System.  
 
As shown in figure 8. The majority of samples identified as positive for Acinetobacter 
baumannii were collected from blood, totaling 42, or 38.1% of the total positives. This was 
followed by samples collected from urine, totalling 16, or 16.5% of the total positive. The third 
most prevalent source was from endotracheal samples, totaling 14, or 12.7% of the total positive 
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3.2.1. Polymerase chain reaction (PCR) 
The purpose of this experiment was to investigate the presence of OXA-69 gene, which signifies 
the presence or positive identification of Acinetobacter baumannii. PCR is a form of genotypic 
test, which bases its identification on the presence or absence of a specific gene or number of 
genes inside a bacterium. 
 
3.2.2. PCR Primer data: 
 
The primers used for the PCR reaction was the OXA-69 gene. Primers OXA-69 Forward and 
OXA-69 Reverse were used for the PCR. The primers and expected fragment size were as shown 
in the materials and methods. 
 
Upon completion of the VITEK-2 identification, the samples were then further identified using 
the PCR method by amplifying the OXA-69 gene. The amplification of this gene is a positive 
genetic indicator of the Acinetobacter baumannii species. 
 
Of the 110 samples, only 88 were identified as positive by OXA-69 PCR, suggesting that the 
VITEK-2 system had an error of 20 %. 
The positive isolates were then pictured below in the gels below showing their bands that 





Figure 9. Gel showing Acinetobacter baumannii  identification using OXA-69 primer for isolates  
1 to 28. M= 1kb ladder. Each lane is in accordance to Table 1, whereby each isolate number is 
recorded above its respective band. Negative lanes 3 and 9 were excluded from the results.  
M      14     15     16    17     18    19     20     21     22    23    24      25     26     27    
28  
  M       1       2        -       3       4       5       6       7       -         8      9      10     11     12     






Figure 10. Gel showing Acinetobacter baumannii identification using OXA-69 primer for 
isolates  29 to 58. M= 1kb ladder 
 
All the above samples in the gel were identified as positive, and each isolate number is recorded 
above its respective lane, and can be referenced with Table 1.    
 
 
M      44     45    46    47     48    49     50     51     52    53     54     55     56    57     
58 







Figure 11. Gel showing Acinetobacter baumannii  identification using OXA-69 primer for 
isolates  59 to 88. M= 1kb ladder  
 
All the above samples in the gel were identified as positive, and each isolate number is recorded 





M      74    75    76    77     78    79    80     81    82    83     84    85    86    87    88 






Figure 12. Bar Chart showing the total male and female number of positive samples isolated and 
their respective sources identified by PCR method.  
 
As shown in figure 12. The majority of samples identified as positive for Acinetobacter 
baumannii were collected from blood, totaling 34, or 38.6% of the total positives. This was 
followed by samples collected from endotracheal, totaling 14, or 15.9% of the total positive. 
Both the third and fourth most prevalent sources were from urine and tip samples, totaling 9, or 
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3.3.Minimal Inhibitory Concentration (MIC) Test Results 
Two of the main carbapenems were used in this study: Meropenem (MEM) and Imipenem 
(IMP). They are considered as the last source of defence from multi-drug resistant (MDR) strains 
of Acinetobacter baumannii (Peleg et al., 2008). 
 
The MIC break points for each sample were recorded under both antibiotic columns (MEM) and 
(IMP), with the resistance (R), intermediacy (I), and sensitivity (S) identified in accordance to 
the British Society for Antimicrobial Chemotherapy (BSAC, 2012) version 11.1 (Table 2).  
 




MIC Breakpoint (mg/L) 























The total number of Acinetobacter baumannii samples from each year is as follows: 2006 = 26 
samples, 2007 = 28 samples and 2008 = 34 samples.  
 
The percentage of isolates resistant to Meropenem was: 23.8% 
The percentage of isolates resistant to Imipenem was: 31.8% 
 
The number of Males with isolates resistant to either of the carbapenems was 19, which accounts 
to 21.5% of the total samples. Whereas the number of females with isolates resistant to either 
carbapenems was 10, accounting for 11.3% of the total samples. 
Overall carbapenem resistance was observed in 55.7% of the total isolates. 
 
While the resistance of Meropenem in each year was as follows: 2006 = 4 samples, (4.5%). 2007 
= 7 samples, (7.9%). 2008 = 10 samples, (11%). (Figures 14 and 16) 
According to each year, resistance of Imipenem was as follows: 2006 = 7 samples, (7.9%). 2007 
= 8 samples, (9%). 2008 = 13 samples, (14.7%). (Figures 15 and 17) 
 
An increase was noticed in the number of resistant bacteria to Imipenem and Meropenem from 
2006 to 2008 as shown in Figure 13 below.  
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Figure 13. Line Graph showing the steady increase in the number of resistant Acinetobacter 
baumannii samples during the years 2006, 2007, 2008.  
 
 





Year Sensitive Intermediate Resistant Total 
Number 
2006 14 8 4 26 
2007 14 7 7 28 





























Figure 14. Bar Chart showing the total number of Meropenem Sensitive, Intermediate, and 
Resistant Acinetobacter baumannii isolates. 
 
 
As shown in table 3 above, the number of Meropenem sensitive, intermediate, and resistant 
Acinetobacter baumannii isolate numbers were all recorded. Figure 14 better describes the table 
information, showing that there was an increase Meropenem resistance and intermediate 
numbers over the years. The highest number of Meropenem resistant samples was noticed to be 
in 2008, also the highest number of Meropenem intermediate samples was also found to be in 
2008. The lowest number of Meropenem resistance was found in 2006. This indicates a clear 
increase in the number of Meropenem resistant samples over the years 2006-2008. There was no 
significant change in the number of sensitive samples over the 3 years, but a slight decrease in 
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Year Sensitive Intermediate Resistant Total  
Number 
2006 16 3 7 26 
2007 10 10 8 28 




Figure 15. Bar Chart showing the total number of Imipenem Sensitive, Intermediate, and 
Resistant Acinetobacter baumannii isolates. 
 
As shown in table 4 above, the number of Imipenem sensitive, intermediate, and resistant 
Acinetobacter baumannii isolate numbers were all recorded. Figure 15 better describes the table 
information, showing that an increase in overall resistance to Imipenem was noticed over the 












Total number of Imipenem sensitive, 






the highest number of Imipenem intermediate samples in 2008. Conversely, the lowest number 
of Imipenem resistant samples was found in 2006, with the lowest number of Imipenem 
intermediate samples also in 2006. This data clearly indicates an increase in the number of 
Imipenem resistant samples over the years 2006-2008. There was a major decrease in the number 













Figure 16.  Showing Stacked Column Bar Chart showing the percentage changes in resistance, 
intermediate, and sensitivity of the Acinetobacter baumannii samples to Meropenem, for the 
years 2006, 2007, 2008. 
 
From the figure 16 above we can clearly see a gradual increase in the overall percentage of 
Meropenem resistant samples, which are shown in the top red bars, and a gradual decrease in the 
percentage of Meropenem sensitive samples, what are shown in the bottom blue bars of the 
stacked column bar chart. The percentage of Meropenem intermediate samples, shown in the 
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Figure 17. Showing. Stacked Column Bar Chart showing the percentage changes in resistance, 
intermediate, and sensitivity of the Acinetobacter baumannii samples to Imipenem, for the years 
2006, 2007, 2008. 
 
From the figure 17 above we can clearly see a slight increase in the overall percentage of 
Imipenem resistant samples, which are shown in the top red bars, but we noticed a significant 
decrease in the percentage of Imipenem sensitive samples, that are shown in the bottom blue bars 
of the stacked column bar chart, from 2006 to 2008. The percentage of Imipenem intermediate 
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Table 5. Shows the samples with their susceptibility to each antibiotic. The sensitive isolates 
were marked in light blue colour, the intermediate in orange and resistant isolates in red.  
 
Table 5. Minimum Inhibitory Concentration (MIC) Test 
Sample 
No. 
Date Sex Source MEM IMP 
1 2006 M Rectal Swab 0.25 0.5 
2 2006 M ICU 4 1 
3 2006 M Rectal Swab 1 1 
4 2006 F Endotracheal 0.25 0.25 
5 2006 M Urine 4 2 
6 2006 M Tip 0.25 0.5 
7 2006 M Urine 16 16 
8 2006 F Urine 2 2 
9 2006 F Blood 16 16 
10 2006 M Blood 2 2 
11 2006 M Blood 1 2 
12 2006 M Tip 0.5 2 
13 2006 M Blood 8 16 
14 2006 M Blood 8 8 
15 2006 M Blood 8 16 
16 2006 M Urine 0.5 2 
17 2006 F ICU 0.12 0.5 
18 2006 F Blood 4 4 
19 2006 M Blood 4 8 
20 2006 M Endotracheal 8 16 
21 2006 F Blood 16 16 
22 2006 M Blood 16 16 
23 2006 F Tip 0.25 0.25 
24 2006 F Tip 0.25 0.5 
25 2006 M Pus Swab 0.12 0.5 
26 2006 M Tissue 0.25 1 
27 2007 M Tissue 0.25 0.25 
28 2007 F Urine 0.03 0.25 
29 2007 F Exit site 
Swab 
0.06 0.12 
30 2007 F Tip 0.5 0.5 
31 2007 M Blood 8 8 
32 2007 M Blood 2 4 
33 2007 M Blood 16 16 
34 2007 M Blood 8 16 
35 2007 M Skin Swab 8 8 
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36 2007 M Blood 16 16 
37 2007 M Blood 8 16 
38 2007 F Blood 4 8 
39 2007 F Endotracheal 2 4 
40 2007 M Endotracheal 0.5 2 
41 2007 F Endotracheal 2 4 
42 2007 F Endotracheal 0.25 1 
43 2007 M Urine 0.12 0.5 
44 2007 F Pus Swab 0.06 0.5 
45 2007 M Endotracheal 1 2 
46 2007 F Endotracheal 8 8 
47 2007 M Sputum 1 4 
48 2007 M Blood 16 32 
49 2007 M Blood 16 16 
50 2007 M Aspiration 
Fluid 
0.5 0.5 
51 2007 M Rectal Swab 8 8 
52 2007 M Pus Swab 16 8 
53 2007 F Pus Swab 16 16 
54 2007 F Pus Swab 16 16 
55 2008 M Blood 16 16 
56 2008 M Endotracheal 0.25 0.5 
57 2008 M Blood 4 16 
58 2008 F Blood 8 4 
59 2008 F Blood 8 8 
60 2008 M Urine 16 16 
61 2008 M Blood 4 8 
62 2008 F Blood 8 16 
63 2008 M Tip 2 4 
64 2008 M Blood 16 16 
65 2008 F Endotracheal 16 16 
66 2008 F Pertonial 0.25 0.25 
67 2008 F Rectal Swab 2 4 
68 2008 M Blood 16 32 
69 2008 M Urine 8 16 
70 2008 F Pus Swab 4 8 
71 2008 F Blood 2 2 
72 2008 M Endotracheal 0.5 0.5 
73 2008 M Tissue 16 32 
74 2008 M Pus Swab 4 4 
75 2008 M Blood 2 4 
76 2008 F Tip 0.015 0.06 
77 2008 M Tip 0.03 0.12 
78 2008 M Endotracheal 2 8 
79 2008 F Urine 2 8 
80 2008 F Blood 4 2 
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81 2008 F Endotracheal 8 8 
82 2008 F Blood 2 8 
83 2008 F Blood 16 16 
84 2008 F Blood 4 4 
85 2008 F Endotracheal 16 16 
86 2008 F Tip 16 16 
87 2008 F Aspiration 
Fluid 
0.03 0.25 





3.4.Sequencing of PCR products 
 
The DNA Sequencing of all 88 OXA-51-like genes confirmed that of the strains, 50% of them, 
were found to contain blaOXA-64, which is a significant percentage and unprecedented 
elsewhere. The results are shown in table 7 as well as the figure 20 showing a percentage pie 
chart of all the isolates in the study. 
 
The first and most prominent OXA-51-like gene found in the samples was the OXA-64, with 
50%. The second most prominent was the OXA-98 which was found in 18% of the isolates. 
OXA-66 was third down the percentage list and was found in 10% of the isolates. OXA-69 and 
OXA-71 were both found in 7% of the isolates. OXA-51 was found in 3% of the isolates. OXA-





All the sequences were cross-checked with the GenBank database before their identification, any 
sequences that were not found in the GenBank were sequenced again to double check for 
mistakes, before being sent to the GenBank database and get published as a newly found OXA 
nucleotide sequence. In this study a new and complete nucleotide sequence for the OXA-117 
enzyme was found, the complete 825 bp sequence data of OXA-117 was then deposited in the 
GenBank nucleotide database under accession number: GQ423625.1  
 
The majority of the OXA-64 containing Acinetobacter baumannii were isolated from blood. 
Whereas the rest of the OXA-51-like genes were not found to be particularly associated with any 
specific source of infection. The samples were varied in their collection source, varying from 










Date Sex Source OXA-51-like 
types 
1 M16 2006 M Rectal Swab 64 
2 M17 2006 M ICU 64 
3 M20 2006 M Rectal Swab 64 
4 M21 2006 F Endotracheal 64 
5 M28 2006 M Urine 64 
6 M35 2006 M Tip 69 
7 M36 2006 M Urine 117 
8 M37 2006 F Urine 69 
9 M48 2006 F Blood 64 
10 M49 2006 M Blood 64 
11 M50 2006 M Blood 64 
12 M51 2006 M Tip 64 
13 M53 2006 M Blood 64 
14 M54 2006 M Blood 64 
15 M55 2006 M Blood 64 
16 M56 2006 M Urine 64 
17 M57 2006 F ICU 51 
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18 M62 2006 F Blood 98 
19 M65 2006 M Blood 64 
20 M66 2006 M Endotracheal 66 
21 M67 2006 F Blood 64 
22 M68 2006 M Blood 64 
23 M71 2006 F Tip 64 
24 M72 2006 F Tip 64 
25 M73 2006 M Pus Swab 98 
26 M74 2006 M Tissue 98 
27 M75 2007 M Tissue 98 
28 M79 2007 F Urine 64 
29 M80 2007 F Rectal Swab 64 
30 M84 2007 F Tip 66 
31 M85 2007 M Blood 64 
32 M86 2007 M Blood 64 
33 M87 2007 M Blood 64 
34 M88 2007 M Blood 64 
35 M89 2007 M Skin Swab 64 
36 M96 2007 M Blood 64 
37 M97 2007 M Blood 64 
38 M100 2007 F Blood 64 
39 M106 2007 F Endotracheal 69 
40 M110 2007 M Endotracheal 69 
41 M113 2007 F Endotracheal 69 
42 M114 2007 F Endotracheal 69 
43 M123 2007 M Urine 64 
44 M140 2007 F Pus Swab 98 
45 M158 2007 M Endotracheal 71 
46 M159 2007 F Endotracheal 70 
47 M160 2007 M Sputum 66 
48 M161 2007 M Blood 98 
49 M165 2007 M Blood 98 
50 M167 2007 M Aspiration 
Fluid 
64 
51 M169 2007 M Exit site 
Swab 
98 
52 M178 2007 M Pus Swab 64 
53 M180 2007 F Pus Swab 98 
54 M184 2007 F Pus Swab 98 
55 K1 2008 M Blood 64 
56 K2 2008 M Endotracheal 64 
57 K5 2008 M Blood 98 
58 K6 2008 F Blood 98 
59 K7 2008 F Blood 66 
60 K8 2008 M Urine 98 
61 K10 2008 M Blood 71 
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62 K11 2008 F Blood 66 
63 K12 2008 M Tip 98 
64 K13 2008 M Blood 68 
65 K15 2008 F Endotracheal 66 
66 K16 2008 F Pertonial 64 
67 K17 2008 F Rectal Swab 64 
68 K18 2008 M Blood 66 
69 K19 2008 M Urine 98 
70 K21 2008 F Pus Swab 106 
71 K24 2008 F Blood 98 
72 K25 2008 M Endotracheal 64 
73 K26 2008 M Tissue 68 
74 K27 2008 M Pus Swab 71 
75 K29 2008 M Blood 51 
76 K30 2008 F Tip 66 
77 K39 2008 M Tip 66 
78 K44 2008 M Endotracheal 64 
79 K45 2008 F Urine 64 
80 K47 2008 F Blood 64 
81 K48 2008 F Endotracheal 64 
82 K88 2008 F Blood 64 
83 K89 2008 F Blood 64 
84 K90 2008 F Blood 71 
85 K93 2008 F Endotracheal 71 
86 K94 2008 F Tip 64 
87 K95 2008 F Aspiration 
Fluid 
71 




The total number of OXA samples that were sequenced was 88. The number of each sequence 
type is shown in table 7 below. OXA-64 was found in the majority of the samples, in 44 samples. 
OXA-98 was the second most prevalent, found in 16 samples, and OXA-66 was third most 
prevalent, found in 9 samples. This study was the first to show the OXA-type distribution for 
Acinetobacter baumannii in Kuwait. In total 10 OXA-types were discovered in the samples 
isolated from the Mubarak Al-Kabeer hospital.  
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Sequence Groups 1,2,3 and 4 were all identified in this study, in accordance to Turton et al, 
(2007). See table 7. 
 
Table 7. Showing all the OXA-types identified in the study, their total number from the samples, 
and the identified sequence groups they represent. 
 
 
OXA-TYPE Number of samples Sequence Group 
OXA-64 44 - 
OXA-69 6 2 
OXA-117 1 - 
OXA-51 2 4 
OXA-98 16 - 
OXA-66 9 1 
OXA-71 6 3 
OXA-70 1 - 
OXA-68 2 - 





Figure 18. Pie Chart showing the distribution of all the blaOXA-51-like  genes identified in Mubarak 
Al-Kabeer Hospital in Kuwait. 
 
 
From the pie chart in Figure 18 above, it can be clearly seen that the majority of the strains 
contained the OXA-64 enzyme, with 50% accounting for them. Next the OXA-98 which was 
found in 18% of the total samples, and followed by OXA-66 which was found in 10% of the 
total Acinetobacter baumannii isolates. Both OXA-71 and OXA-69 were found in 7% of the 

























3.5.Nucleotide Sequence Result Comparisons 
Below is the series of Nucleotide Sequence results which were identified, and each compared to 
the OXA-64 sequence, because it was more prevalent in this study. 




3.5.1. OXA-64 and OXA-71 
 
OXA-64 1    ATGAACATTAAAGCACTCTTACTTATAACAAGCGCTATTTTTATTTCAGCCTGCTCACCT  60 
            |||||||||||||| ||||||||||||||||||||||||||||||||||||||||||||| 
OXA-71 1    ATGAACATTAAAGCCCTCTTACTTATAACAAGCGCTATTTTTATTTCAGCCTGCTCACCT  60 
 
OXA-64 61   TATATAGTGACTGCTAATCCAAATCACAGCGCTTCAAAATCTGATGAAAAAGGAGAGAAA  120 
            |||||||||||||||||||||||||||||||||||||||||||||||||||| ||||||| 
OXA-71 61   TATATAGTGACTGCTAATCCAAATCACAGCGCTTCAAAATCTGATGAAAAAGCAGAGAAA  120 
 
OXA-64 121  ATTAAAAATTTATTTAACGAAGCACACACTACGGGTGTTTTAGTTATCCAACAAGGCCAA  180 
            |||||||||||||||||||||||||||||||||||||| ||||||||||||||||||||| 
OXA-71 121  ATTAAAAATTTATTTAACGAAGCACACACTACGGGTGTCTTAGTTATCCAACAAGGCCAA  180 
 
OXA-64 181  ACTCAACAAAGCTATGGTAATGATCTTGCTCGTGCTTCGACCGAGTATGTACCTGCTTCG  240 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
OXA-71 181  ACTCAACAAAGCTATGGTAATGATCTTGCTCGTGCTTCGACCGAGTATGTACCTGCTTCG  240 
 
OXA-64 241  ACCTTCAAAATGCTTAATGCTTTGATCGGCCTTGAGCACCATAAGGCAACCACCACAGAA  300 
            ||||||||||||||||||||||||||||||||||||||||||||| |||||||||||||| 
OXA-71 241  ACCTTCAAAATGCTTAATGCTTTGATCGGCCTTGAGCACCATAAGACAACCACCACAGAA  300 
 
OXA-64 301  GTATTTAAGTGGGACGGGCAAAAAAGGCTATTCCCAGAATGGGAAAAGGACATGACCCTA  360 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
OXA-71 301  GTATTTAAGTGGGACGGGCAAAAAAGGCTATTCCCAGAATGGGAAAAGGACATGACCCTA  360 
 
OXA-64 361  GGCGATGCTATGAAAGCTTCCGCTATTCCGGTTTATCAAGATTTAGCTCGTCGTATTGGA  420 
            ||||| |||||||||||||||||||||||||||||||||||||||||||||||||||||| 
OXA-71 361  GGCGACGCTATGAAAGCTTCCGCTATTCCGGTTTATCAAGATTTAGCTCGTCGTATTGGA  420 
 
OXA-64 421  CTTGAACTCATGTCTAAGGAAGTGAAGCGTGTTGGTTATGGCAATGCAGATATCGGTACC  480 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
OXA-71 421  CTTGAACTCATGTCTAAGGAAGTGAAGCGTGTTGGTTATGGCAATGCAGATATCGGTACC  480 
 
OXA-64 481  CAAGTCGATAATTTTTGGCTGGTGGGTCCTTTAAAAATTACTCCTCAGCAAGAGGCACAG  540 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||  
OXA-71 481  CAAGTCGATAATTTTTGGCTGGTGGGTCCTTTAAAAATTACTCCTCAGCAAGAGGCACAA  540 
 
OXA-64 541  TTTGCTTACAAGCTAGCTAATAAAACGCTTCCATTTAGCCCAAAAGTCCAAGATGAAGTG  600 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
OXA-71 541  TTTGCTTACAAGCTAGCTAATAAAACGCTTCCATTTAGCCCAAAAGTCCAAGATGAAGTG  600 
 
OXA-64 601  CAATCCATGTTATTCATAGAAGAAAAGAATGGAAATAAAATATACGCAAAAAGTGGTTGG  660 
            ||||||||| |||||||||||||||||||||||||||||||||||||||||||||||||| 




OXA-64 661  GGATGGGATGTAGACCCACAAGTAGGCTGGTTAACTGGATGGGTTGTTCAGCCTCAAGGG  720 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||  
OXA-71 661  GGATGGGATGTAGACCCACAAGTAGGCTGGTTAACTGGATGGGTTGTTCAGCCTCAAGGA  720 
 
OXA-64 721  AATATTGTAGCGTTCTCCCTTAACTTAGAAATGAAAAAAGGAATACCTAGCTCTGTTCGA  780 
            ||||||||||| |||||||||||||||||||||||||||||||||||||||||||||||| 
OXA-71 721  AATATTGTAGCATTCTCCCTTAACTTAGAAATGAAAAAAGGAATACCTAGCTCTGTTCGA  780 
 
OXA-64 781  AAAGAGATTACTTATAAAAGTTTAGAACAATTAGGTATTTTATAG  825 
            ||||||||||||||||||||||||||||||||||||||||||||| 
OXA-71 781  AAAGAGATTACTTATAAAAGTTTAGAACAATTAGGTATTTTATAG  825 
 
3.5.2. OXA-64 and OXA-66 
 
OXA-64 1    ATGAACATTAAAGCACTCTTACTTATAACAAGCGCTATTTTTATTTCAGCCTGCTCACCT  60 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
OXA-66 1    ATGAACATTAAAGCACTCTTACTTATAACAAGCGCTATTTTTATTTCAGCCTGCTCACCT  60 
 
OXA-64 61   TATATAGTGACTGCTAATCCAAATCACAGCGCTTCAAAATCTGATGAAAAAGGAGAGAAA  120 
            |||||||||||||||||||||||||||||||||||||||||||||| ||||| ||||||| 
OXA-66 61   TATATAGTGACTGCTAATCCAAATCACAGCGCTTCAAAATCTGATGTAAAAGCAGAGAAA  120 
 
OXA-64 121  ATTAAAAATTTATTTAACGAAGCACACACTACGGGTGTTTTAGTTATCCAACAAGGCCAA  180 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
OXA-66 121  ATTAAAAATTTATTTAACGAAGCACACACTACGGGTGTTTTAGTTATCCAACAAGGCCAA  180 
 
OXA-64 181  ACTCAACAAAGCTATGGTAATGATCTTGCTCGTGCTTCGACCGAGTATGTACCTGCTTCG  240 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
OXA-66 181  ACTCAACAAAGCTATGGTAATGATCTTGCTCGTGCTTCGACCGAGTATGTACCTGCTTCG  240 
 
OXA-64 241  ACCTTCAAAATGCTTAATGCTTTGATCGGCCTTGAGCACCATAAGGCAACCACCACAGAA  300 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
OXA-66 241  ACCTTCAAAATGCTTAATGCTTTGATCGGCCTTGAGCACCATAAGGCAACCACCACAGAA  300 
 
OXA-64 301  GTATTTAAGTGGGACGGGCAAAAAAGGCTATTCCCAGAATGGGAAAAGGACATGACCCTA  360 
            |||||||||||||| ||  |||||||| |||||||||||||||||||||||||||||||| 
OXA-66 301  GTATTTAAGTGGGATGGTAAAAAAAGGTTATTCCCAGAATGGGAAAAGGACATGACCCTA  360 
 
OXA-64 361  GGCGATGCTATGAAAGCTTCCGCTATTCCGGTTTATCAAGATTTAGCTCGTCGTATTGGA  420 
            |||||||| |||||||||||||||||||| |||||||||||||||||||||||||||||| 
OXA-66 361  GGCGATGCCATGAAAGCTTCCGCTATTCCAGTTTATCAAGATTTAGCTCGTCGTATTGGA  420 
 
OXA-64 421  CTTGAACTCATGTCTAAGGAAGTGAAGCGTGTTGGTTATGGCAATGCAGATATCGGTACC  480 
            ||||| |||||||||||||||||||||||||||||||||||||||||||||||||||||| 
OXA-66 421  CTTGAGCTCATGTCTAAGGAAGTGAAGCGTGTTGGTTATGGCAATGCAGATATCGGTACC  480 
 
OXA-64 481  CAAGTCGATAATTTTTGGCTGGTGGGTCCTTTAAAAATTACTCCTCAGCAAGAGGCACAG  540 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
OXA-66 481  CAAGTCGATAATTTTTGGCTGGTGGGTCCTTTAAAAATTACTCCTCAGCAAGAGGCACAG  540 
 
OXA-64 541  TTTGCTTACAAGCTAGCTAATAAAACGCTTCCATTTAGCCCAAAAGTCCAAGATGAAGTG  600 
            |||||||||||||||||||||||||||||||||||||||| ||||||||||||||||||| 
OXA-66 541  TTTGCTTACAAGCTAGCTAATAAAACGCTTCCATTTAGCCAAAAAGTCCAAGATGAAGTG  600 
 
OXA-64 601  CAATCCATGTTATTCATAGAAGAAAAGAATGGAAATAAAATATACGCAAAAAGTGGTTGG  660 
            ||||||||| ||||||||||||||||||||||||| |||||||||||||||||||||||| 
OXA-66 601  CAATCCATGCTATTCATAGAAGAAAAGAATGGAAACAAAATATACGCAAAAAGTGGTTGG  660 
 
OXA-64 661  GGATGGGATGTAGACCCACAAGTAGGCTGGTTAACTGGATGGGTTGTTCAGCCTCAAGGG  720 
            |||||||||||| ||||||||||||||||||||||||||||||||||||||||||||||| 
OXA-66 661  GGATGGGATGTAAACCCACAAGTAGGCTGGTTAACTGGATGGGTTGTTCAGCCTCAAGGG  720 
 
OXA-64 721  AATATTGTAGCGTTCTCCCTTAACTTAGAAATGAAAAAAGGAATACCTAGCTCTGTTCGA  780 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
OXA-66 721  AATATTGTAGCGTTCTCCCTTAACTTAGAAATGAAAAAAGGAATACCTAGCTCTGTTCGA  780 
 
OXA-64 781  AAAGAGATTACTTATAAAAGTTTAGAACAATTAGGTATTTTATAG  825 
            |||||||||||||||||||| |||||||||||||||||||||||| 
OXA-66 781  AAAGAGATTACTTATAAAAGCTTAGAACAATTAGGTATTTTATAG  825 
69 
 
3.5.3. OXA-64 and OXA-69 
OXA-64 1    ATGAACATTAAAGCACTCTTACTTATAACAAGCGCTATTTTTATTTCAGCCTGCTCACCT  60 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
OXA-69 1    ATGAACATTAAAGCACTCTTACTTATAACAAGCGCTATTTTTATTTCAGCCTGCTCACCT  60 
 
OXA-64 61   TATATAGTGACTGCTAATCCAAATCACAGCGCTTCAAAATCTGATGAAAAAGGAGAGAAA  120 
            ||||||||||||||||||||||||||||| ||||||||||||||||| |||| ||||||| 
OXA-69 61   TATATAGTGACTGCTAATCCAAATCACAGTGCTTCAAAATCTGATGACAAAGCAGAGAAA  120 
 
OXA-64 121  ATTAAAAATTTATTTAACGAAGCACACACTACGGGTGTTTTAGTTATCCAACAAGGCCAA  180 
            |||||||||||||||||||||||||||||||||||||||||||||||||| ||||| ||| 
OXA-69 121  ATTAAAAATTTATTTAACGAAGCACACACTACGGGTGTTTTAGTTATCCATCAAGGTCAA  180 
 
OXA-64 181  ACTCAACAAAGCTATGGTAATGATCTTGCTCGTGCTTCGACCGAGTATGTACCTGCTTCG  240 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
OXA-69 181  ACTCAACAAAGCTATGGTAATGATCTTGCTCGTGCTTCGACCGAGTATGTACCTGCTTCG  240 
 
OXA-64 241  ACCTTCAAAATGCTTAATGCTTTGATCGGCCTTGAGCACCATAAGGCAACCACCACAGAA  300 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
OXA-69 241  ACCTTCAAAATGCTTAATGCTTTGATCGGCCTTGAGCACCATAAGGCAACCACCACAGAA  300 
 
OXA-64 301  GTATTTAAGTGGGACGGGCAAAAAAGGCTATTCCCAGAATGGGAAAAGGACATGACCCTA  360 
            |||||||| ||||| ||| ||||||||||||||||||||||||||||| ||||||||||| 
OXA-69 301  GTATTTAAATGGGATGGGGAAAAAAGGCTATTCCCAGAATGGGAAAAGAACATGACCCTA  360 
 
OXA-64 361  GGCGATGCTATGAAAGCTTCCGCTATTCCGGTTTATCAAGATTTAGCTCGTCGTATTGGA  420 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
OXA-69 361  GGCGATGCTATGAAAGCTTCCGCTATTCCGGTTTATCAAGATTTAGCTCGTCGTATTGGA  420 
 
OXA-64 421  CTTGAACTCATGTCTAAGGAAGTGAAGCGTGTTGGTTATGGCAATGCAGATATCGGTACC  480 
            ||||| |||||||||||||||||||||||||||||||||||||||||||||||||||||| 
OXA-69 421  CTTGAGCTCATGTCTAAGGAAGTGAAGCGTGTTGGTTATGGCAATGCAGATATCGGTACC  480 
 
OXA-64 481  CAAGTCGATAATTTTTGGCTGGTGGGTCCTTTAAAAATTACTCCTCAGCAAGAGGCACAG  540 
            |||||||||||||||||||||||||||||| ||||||||||||||||||||||||||||| 
OXA-69 481  CAAGTCGATAATTTTTGGCTGGTGGGTCCTCTAAAAATTACTCCTCAGCAAGAGGCACAG  540 
 
OXA-64 541  TTTGCTTACAAGCTAGCTAATAAAACGCTTCCATTTAGCCCAAAAGTCCAAGATGAAGTG  600 
            |||||||||||||||||||||||||||||||||||||||| ||||||||||||||||||| 
OXA-69 541  TTTGCTTACAAGCTAGCTAATAAAACGCTTCCATTTAGCCAAAAAGTCCAAGATGAAGTG  600 
 
OXA-64 601  CAATCCATGTTATTCATAGAAGAAAAGAATGGAAATAAAATATACGCAAAAAGTGGTTGG  660 
            ||||||||| |||||||||||||||||||||||||||||||||||||||||||||||||| 
OXA-69 601  CAATCCATGCTATTCATAGAAGAAAAGAATGGAAATAAAATATACGCAAAAAGTGGTTGG  660 
 
OXA-64 661  GGATGGGATGTAGACCCACAAGTAGGCTGGTTAACTGGATGGGTTGTTCAGCCTCAAGGG  720 
            |||||||||||| ||||||||||||||||||||||||||||||||||||||||||||||| 
OXA-69 661  GGATGGGATGTAAACCCACAAGTAGGCTGGTTAACTGGATGGGTTGTTCAGCCTCAAGGG  720 
 
OXA-64 721  AATATTGTAGCGTTCTCCCTTAACTTAGAAATGAAAAAAGGAATACCTAGCTCTGTTCGA  780 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
OXA-69 721  AATATTGTAGCGTTCTCCCTTAACTTAGAAATGAAAAAAGGAATACCTAGCTCTGTTCGA  780 
 
OXA-64 781  AAAGAGATTACTTATAAAAGTTTAGAACAATTAGGTATTTTATAG  825 
            ||||||||||||||||||||||||||||||||||||||||||||| 










3.6.Protein sequence comparison 
 
Below is the series of Protein Sequence results which were identified, and each compared to the 
OXA-64 sequence, because it was more prevalent in this study. 
The highlighted amino acids represent the differences between each of the respective OXA types 
in this analysis. 
 
3.6.1. OXA-64 and OXA-71 
 
OXA-64 1    MNIKALLLITSAIFISACSPYIVTANPNHSASKSDEKGEKIKNLFNEAHTTGVLVIQQGQ  60 
            MNIKALLLITSAIFISACSPYIVTANPNHSASKSDEK EKIKNLFNEAHTTGVLVIQQGQ 
OXA-71 1    MNIKALLLITSAIFISACSPYIVTANPNHSASKSDEKAEKIKNLFNEAHTTGVLVIQQGQ  60 
 
OXA-64 61   TQQSYGNDLARASTEYVPASTFKMLNALIGLEHHKATTTEVFKWDGQKRLFPEWEKDMTL  120 
            TQQSYGNDLARASTEYVPASTFKMLNALIGLEHHK TTTEVFKWDGQKRLFPEWEKDMTL 
OXA-71 61   TQQSYGNDLARASTEYVPASTFKMLNALIGLEHHKTTTTEVFKWDGQKRLFPEWEKDMTL  120 
 
OXA-64 121  GDAMKASAIPVYQDLARRIGLELMSKEVKRVGYGNADIGTQVDNFWLVGPLKITPQQEAQ  180 
            GDAMKASAIPVYQDLARRIGLELMSKEVKRVGYGNADIGTQVDNFWLVGPLKITPQQEAQ 
OXA-71 121  GDAMKASAIPVYQDLARRIGLELMSKEVKRVGYGNADIGTQVDNFWLVGPLKITPQQEAQ  180 
 
OXA-64 181  FAYKLANKTLPFSPKVQDEVQSMLFIEEKNGNKIYAKSGWGWDVDPQVGWLTGWVVQPQG  240 
            FAYKLANKTLPFSPKVQDEVQSMLFIEEKNGNKIYAKSGWGWDVDPQVGWLTGWVVQPQG 
OXA-71 181  FAYKLANKTLPFSPKVQDEVQSMLFIEEKNGNKIYAKSGWGWDVDPQVGWLTGWVVQPQG  240 
 
OXA-64 241  NIVAFSLNLEMKKGIPSSVRKEITYKSLEQLGIL  274 
            NIVAFSLNLEMKKGIPSSVRKEITYKSLEQLGIL 
OXA-71 241  NIVAFSLNLEMKKGIPSSVRKEITYKSLEQLGIL  274 
 
 
3.6.2. OXA-64 and OXA-66 
OXA-64 1    MNIKALLLITSAIFISACSPYIVTANPNHSASKSDEKGEKIKNLFNEAHTTGVLVIQQGQ  60 
            MNIKALLLITSAIFISACSPYIVTANPNHSASKSD K EKIKNLFNEAHTTGVLVIQQGQ 
OXA-66 1    MNIKALLLITSAIFISACSPYIVTANPNHSASKSDVKAEKIKNLFNEAHTTGVLVIQQGQ  60 
 
OXA-64 61   TQQSYGNDLARASTEYVPASTFKMLNALIGLEHHKATTTEVFKWDGQKRLFPEWEKDMTL  120 
            TQQSYGNDLARASTEYVPASTFKMLNALIGLEHHKATTTEVFKWDG+KRLFPEWEKDMTL 
OXA-66 61   TQQSYGNDLARASTEYVPASTFKMLNALIGLEHHKATTTEVFKWDGKKRLFPEWEKDMTL  120 
 
OXA-64 121  GDAMKASAIPVYQDLARRIGLELMSKEVKRVGYGNADIGTQVDNFWLVGPLKITPQQEAQ  180 
            GDAMKASAIPVYQDLARRIGLELMSKEVKRVGYGNADIGTQVDNFWLVGPLKITPQQEAQ 
OXA-66 121  GDAMKASAIPVYQDLARRIGLELMSKEVKRVGYGNADIGTQVDNFWLVGPLKITPQQEAQ  180 
 
OXA-64 181  FAYKLANKTLPFSPKVQDEVQSMLFIEEKNGNKIYAKSGWGWDVDPQVGWLTGWVVQPQG  240 
            FAYKLANKTLPFS KVQDEVQSMLFIEEKNGNKIYAKSGWGWDV+PQVGWLTGWVVQPQG 
OXA-66 181  FAYKLANKTLPFSQKVQDEVQSMLFIEEKNGNKIYAKSGWGWDVNPQVGWLTGWVVQPQG  240 
 
OXA-64 241  NIVAFSLNLEMKKGIPSSVRKEITYKSLEQLGIL  274 
            NIVAFSLNLEMKKGIPSSVRKEITYKSLEQLGIL 
OXA-66 241  NIVAFSLNLEMKKGIPSSVRKEITYKSLEQLGIL  274 
71 
 
3.6.3. OXA-64 and OXA-69 
 
OXA-64 1    MNIKALLLITSAIFISACSPYIVTANPNHSASKSDEKGEKIKNLFNEAHTTGVLVIQQGQ  60 
            MNIKALLLITSAIFISACSPYIVTANPNHSASKSD+K EKIKNLFNEAHTTGVLVI QGQ 
OXA-69 1    MNIKALLLITSAIFISACSPYIVTANPNHSASKSDDKAEKIKNLFNEAHTTGVLVIHQGQ  60 
 
OXA-64 61   TQQSYGNDLARASTEYVPASTFKMLNALIGLEHHKATTTEVFKWDGQKRLFPEWEKDMTL  120 
            TQQSYGNDLARASTEYVPASTFKMLNALIGLEHHKATTTEVFKWDG+KRLFPEWEK+MTL 
OXA-69 61   TQQSYGNDLARASTEYVPASTFKMLNALIGLEHHKATTTEVFKWDGEKRLFPEWEKNMTL  120 
 
OXA-64 121  GDAMKASAIPVYQDLARRIGLELMSKEVKRVGYGNADIGTQVDNFWLVGPLKITPQQEAQ  180 
            GDAMKASAIPVYQDLARRIGLELMSKEVKRVGYGNADIGTQVDNFWLVGPLKITPQQEAQ 
OXA-69 121  GDAMKASAIPVYQDLARRIGLELMSKEVKRVGYGNADIGTQVDNFWLVGPLKITPQQEAQ  180 
 
OXA-64 181  FAYKLANKTLPFSPKVQDEVQSMLFIEEKNGNKIYAKSGWGWDVDPQVGWLTGWVVQPQG  240 
            FAYKLANKTLPFS KVQDEVQSMLFIEEKNGNKIYAKSGWGWDV+PQVGWLTGWVVQPQG 
OXA-69 181  FAYKLANKTLPFSQKVQDEVQSMLFIEEKNGNKIYAKSGWGWDVNPQVGWLTGWVVQPQG  240 
 
OXA-64 241  NIVAFSLNLEMKKGIPSSVRKEITYKSLEQLGIL  274 
            NIVAFSLNLEMKKGIPSSVRKEITYKSLEQLGIL 


















3.7.Complete Nucleotide and Protein sequence of novel OXA-117 
 
This study was able to uncover the complete gene sequence of the OXA-117 gene. The sequence 
was submitted to GenBank and accepted under accession number: GQ423625 
The complete sequence from the start codon to the end codon in shown below: 
 












               End codon  
 
 

















3.8.DeepView Imaging  
 
DeepView was used to create a 3D structure of OXA-66, OXA-69, OXA-71, OXA-64. They are 
shown below in figures 19, 20, 21, 22 respectively. 
 
The DeepView software was used to calculate the distance in Å between the SERINE active site 
and the respective amino acid that are different than those of OXA-64. A distance of less than 10 
Å was used to signify if the amino acid change had any significant effect on the active site and 
thus the bacteria, or not. 
 
The positions of the amino acid, and properties of each amino acid, which are close to the 67 
Serine active site in Acinetobacter baumannii, are described in table 8 below. Changes in the 
amino acids in each OXA type enzyme have not shown to have distances of less than 10 Å. 
Therefore it was concluded that the resistance or properties were unaltered by the change in 











Table 8. The positions and properties of each amino acid 
 
 














Polar, negative pH 
Nonpolar, neutral 







Nonpolar, neutral pH 

















Polar, neutral pH 
Nonpolar, neutral pH 













Figure 19. OXA-66 showing the distance between the Serine active site and: Valine (Val) = 
26.033 Å, Glutamine (Gln) = 21.638 Å, and Lysine (Lys) = 22.082 Å.  




Figure 20. OXA-69 showing the distance between the Serine active site and:  Aspartic acid (Asp) 






Figure 21. OXA-71 showing the distance between the Serine active site and:  Threonine (Thr) = 





Figure 22. OXA-64 showing the distance between the Serine active site and:  Glycine (Gly) = 
27.778 Å, Glutamic acid (Glu) = 26.039 Å, Proline (Pro) = 21.931 Å, Alanine (Ala) = 17.271 Å, 






3.9.Pulsed-Field Gel Electrophoresis (PFGE) 
 
Pulsed-Field Gel electrophoresis (PFGE) is considered to be the standard method for genotyping 
a large variety of bacterial organisms, which has helped it become a major method in molecular 
diagnosis and epidemiology. In clinical microbiology, the detection and proper identification of 
virulent strains is very important, for only if and once a contagious strain is identified, the 
suitable medication may be given. The clonality of strains, whether they belong to the same 
clone group, or are spontaneous bacterial infections, can be identified using PFGE, which makes 
it a crucial epidemiological tool as well as a hospital diagnostic lab tool. Furthermore, the use of 
PFGE helps in the understanding of the phylogeny of each strain, providing information on 
horizontal gene transfer and gene conversion, genomic rearrangements, and the modular 
organization of chromosomes (Lahti, 1996). 
 
Interpreting and understanding the epidemiology and clonal type of an organism may be 
ascertained by PFGE typing, and comparing the different bands of DNA from the genome of A. 
baumannii strains, following digestion with the restriction endonuclease enzyme Apa1 and 
analysing the generated fragments (Seifert et al., 1994a). 
 
PFGE typing was used to analyse 88 clinical isolates of Acinetobacter baumannii obtained from 
the Mubarak Al-Kabeer hospital over the three year period 2006-2008.  Their gels are shown in 





Figure 23. PFGE patterns showing isolates M16-M49.  
 
Lane L:  Lambda ladder PFG markers standard size. Lane 1: isolate M16. Lane 2: isolate M17. 
Lane 3: isolate M20. Lane 4: isolate M21. Lane 5: isolate M28. Lane 6: isolate M35. Lane 7: 
isolate M36. Lane 8: 
isolate M37. Lane 9: isolate M48. Lane 10: isolate M49. 
 
 
According to the sequencing results, and to better describe the Gel above, the respective isolates 
and their OXA-types are mentioned: Isolates M16,M17,M20,M21,M28,M48,M49 are positive 
for OXA-64. Isolates M35,M37 are positive for OXA-69. Isolates M36 was positive for OXA-





Figure 24. PFGE patterns of isolates M50-M67. 
 
Lanes M: Lambda ladder PFG markers standard size. Lane 1: isolate M50. Lane 2: isolate M51. 
Lane 3: isolate M53. Lane 4: isolate M54. 
Lane 5: isolate M55. Lane 6: isolate M56. Lane 7: isolate M66. Lane 8: 
isolate M67. Lane 9: isolate M68. 
 
 
According to the sequencing results, and to better describe the Gel above, the respective isolates 
and their OXA-types are mentioned: Isolates M50, M51, M53, M54, M55, M56, M65, M67 were 







Figure 25. PFGE patterns of isolates M71-M88. 
 
Lanes M: Lambda ladder PFG markers standard size. Lane 1: isolate M71. Lane 2: isolate M72. 
Lane 3: isolate M73. Lane 4: isolate M74. 
Lane 5: isolate M75. Lane 6: isolate M79. Lane 7: isolate M80. Lane 8: isolate M84. Lane 9: 
isolate M85. Lane 10: isolate M86. Lane 9: isolate M87. Lane 11: isolate M88. 
 
 
According to the sequencing results, and to better describe the Gel above, the respective isolates 
and their OXA-types are mentioned: Isolates M71, M72, M79, M80, M84, M85, M86, M87, 
M88 were all positive for OXA-64. Isolates M73, M74, M75 were positive for OXA-98. Isolate 





Figure 26. PFGE patterns of isolates M89-M160. 
 
 Lanes M: Lambda ladder PFG markers standard size. Lane 1: isolate M89. Lane 2: isolate M96. 
Lane 3: isolate M97. Lane 4: isolate M100. Lane 5: isolate M106. Lane 6: isolate M113. Lane 7: 
isolate M114. Lane 8: isolate M123. Lane 9: isolate M140. Lane 10: isolate M158. Lane 9: 
isolate M159. Lane 11: isolate M160. 
 
According to the sequencing results, and to better describe the Gel above, the respective isolates 
and their OXA-types are mentioned: Isolates M89, M96, M97, M100, M123 were all positive for 
OXA-64. Isolates M106, M113, M114 were positive for OXA-69. Isolates M160 was positive 
for OXA-66. Isolates 158 and 159 are positive for OXA-71 and OXA-70 respectively. Apa1 





Figure 27. PFGE patterns of isolates M161-K7. 
 
Lanes M: Lambda ladder PFG markers standard size. Lane 1: isolate M161. Lane 2: isolate 
M165. Lane 3: isolate M167. Lane 4: isolate M169. Lane 5: isolate M178. Lane 6: isolate M180. 
Lane 7: isolate M184. Lane 8: isolate K1. Lane 9: isolate K2. Lane 10: isolate K3. Lane 9: isolate 
K5. Lane 11: isolate K6. Lane 12: isolate K7 
 
 
According to the sequencing results, and to better describe the Gel above, the respective isolates 
and their OXA-types are mentioned: Isolates M167, M178, K1, K2, K7 were all positive for 
OXA-64. Isolates M161, M165, M169, M180, M184, K5, K6 were all positive for OXA-98. 





Figure 28. PFGE patterns of isolates K8-K39.  
 
Lanes M: Lambda ladder PFG markers standard size. Lane 1: isolate K8. Lane 2: isolate K10. 
Lane 3: isolate K11. Lane 4: isolate K12. Lane 5: isolate K13. Lane 6: isolate K15. Lane 7: 
isolate K16. Lane 8: isolate K18. Lane 9: isolate K19. Lane 10: isolate K25. Lane 9: isolate K27. 
Lane 11: isolate K30. Lane 12: isolate K39 
 
 
According to the sequencing results, and to better describe the Gel above, the respective isolates 
and their OXA-types are mentioned: Isolates K16, K25 were positive for OXA-64. Isolates K11, 
K15, K30, K39 were positive for OXA-66. Isolates K10 and K27 were positive for OXA-71. 





Figure 29. PFGE patterns of isolates K44-M62.  
 
Lanes M: Lambda ladder PFG markers standard size. Lane 1: isolate K44. Lane 2: isolate K45. 
Lane 3: isolate K47. Lane 4: isolate K48  Lane 5: isolate K88. Lane 6: isolate K89. Lane 7: 
isolate K90. Lane 8: isolate K93. Lane 9: isolate K94. Lane 10: isolate K95. Lane 9: isolate K97. 
Lane 11: isolate M57. Lane 12: isolate M62. 
 
According to the sequencing results, and to better describe the Gel above, the respective isolates 
and their OXA-types are mentioned: Isolates K44, K45, K47, K48, K89, K94, K97 were positive 
for OXA-64. Isolates K90, K93, K95 were positive to OXA-71.  Isolates M57 and M62 were 





A Dendogram, shown in figure 30, was made to help better understand the clonality of the 
isolates, and their relatedness to each other. We could see that the OXA-64 isolates were all 
clonal, from the years 2006 till 2008. The same is true about OXA-98, OXA-66, and OXA-71 
which has patterns that are the same throughout the 3 years of study. They are all more than 80% 
similar and in some cases over 90%. There were no clear relatedness to the other OXAs in this 
study, which mean that they are not clones, and individual cases.  
 
This shows that the 4 major clones OXA-64, OXA-71, OXA98, and OXA-66 have survived any 
attempt by the Mubarak Al-Kabeer hospital to eradicate the pathogen from their patients. One 
could also deduce that, if these patients were not infected nosocomially, then these four OXA-
types are more wide spread in Kuwait than expected, which warrants further research into the 
depth of spread and dissemination of these four OXA types in Kuwait. 
 
Figure 30. Below shows a Dendogram showing the Clonality of the Isolates, along with the year 
of collection, gender of the patients collected from, MIC to Imipenem and Meropenem, and 
















































































































































































































































































































































































































































































































































































































































































































































































Bacteria of the genus Acinetobacter are important opportunistic pathogens that are responsible 
for nosocomial infections. Acinetobacter species are highly resistant to commonly used 
antibiotics such as penicillins, cephalosporins, aminoglycosides and fluoroquinolones by 
intrinsic and acquired mechanisms. They are also gradually becoming resistant to carbapenems, 
as this study has shown, in Kuwait.  
 
Hospitals have long served as reservoirs for the transmission of pathogenic bacteria, and this has 
become a problem in Kuwait. Regrettably, little research has been devoted to investigating the 
prevalence, resistance and pathogenicity of Acinetobacter baumannii in Kuwait Hospitals. 
This study examined the resistance profiles and identified the genotypic changes in 
Acinetobacter baumannii as it spread through Mubarak Al-Kabeer Hospital during the years 
2006-2008. 
 
Research in Kuwait has shown that there have been numerous outbreaks of Acinetobacter 
baumannii in several hospitals (Al-Sweih et al., 2011). A variation in the number of clone types 
was also shown in the study. This coincides with the results that I have shown, where in the 
Mubarak Al-Kabeer Hospital, one of the major hospitals in Kuwait, the variation of 
Acinetobacter baumannii clones ranged from European Clone 1, 2, and 3. 
 
This study demonstrated high resistance to carbapenems in Acinetobacter baumannii isolates that 
were collected from patients in Mubarak Al-Kabeer Hospital in Kuwait. The increase in 
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Acinetobacter baumannii carbapenem resistance is becoming a worldwide phenomenon, but with 
some variation in the carbapenem resistance numbers from one geographical area to another. 
There have also been reports of an increase of 6% in 1998 which increased to approximately 
29% in 2005 of Meropenem resistant Acinetobacter baumannii (Perez et al,. 2007). This study 
also confirms this report since there was a noticeable gradual increase in the number of 
Imipenem and Meropenem resistant Acinetobacter baumannii isolates over the course of this 
study. 
 
The presence of bla-OXA-51-like beta-lactamases in Acinetobacter baumannii has a major role 
in the resistance to carbapenems. These beta-lactamases which have a role in carbapenem 
resistance appear to be globally spread (Poirel and Nordmann, 2006a), and recent studies also 
included Middle Eastern countries such as Iraq (Scott et al., 2007), Kuwait (Al-Sweih et al., 
2011), Saudi Arabia (AlSultan et al., 2009), Bahrain (Mugnier et al., 2009) and the United Arab 
Emirates (Mugnier et al., 2008). 
 
 
The identification of Acinetobacter baumannii phenotypically is a difficult problem due to 
significant phenotypic overlapping between strains, which are genotypically closely related to 
each other. (Dolzani et al., 1995) 
 
 
The blaOXA-51-like gene is present intrinsically and is naturally located in all Acinetobacter 
baumannii (Brown et al., 2006), therefore the OXA-69 primer was used to identify the isolates in 
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the PCR identification part, and also give a complete gene sequence later in the sequencing part 
of the study. 
 
From the 120 samples, 110 were identified as Acinetobacter baumannii positive by the VITEK-2 
system method, which is a phenotypic method of identification. 
The percentage of female patients with positive Acinetobacter baumannii was calculated as 
being 49.1%, and the percentage of male patients with positive Acinetobacter baumannii was 
50.9%. 
 
The majority of samples that have been identified phenotypically via the VITEK-2 system as 
positive for Acinetobacter baumannii were collected from: blood, which totalled 42 samples, or 
38.09% of the total positives, there may be several reasons for this, however in the absence of 
clinical records of the patients, it is difficult to reach a clear conclusion explaining it. Further 
study is needed in the hospital ward and the individual patients to better understand the nature of 
their disease and cause of it. One could speculate that open wound infections could provide a 
direct opening to the blood and internal tissues that could help the pathogen in infecting the 
patients. 
 
The other sample sources included urine, which totaled 16, or 16.5% of the total positive, 
endotracheal samples, which totaled 14, or 12.7% of the total positive sample, and the fourth 
prevalent source was from Tip samples, that totaled 10, or 9.1%. According to the genotypic test 
of PCR, Of the 110 samples, only 88 were identified as positive for Acinetobacter baumannii, by 
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OXA-69 PCR. This difference in results suggests that the VITEK-2 system in this study had an 
error of 20% and thus is probably unreliable as a method to detect Acinetobacter baumannii 
 
While the VITEK-2 system is a faster, less expensive and less laborious method, one should not 
ignore the possible erroneous or inaccurate identification it may provide, and in some cases, 
using genotypic methods, such as PCR for OXA-69, for identification are a more solid source of 
identifying Acinetobacter baumannii.  
 
From the genotypic method, we also deduce that the percentage of males and females positive 
for Acinetobacter baumannii was calculated as being 56.8% for females and 43.2% for males, 
not denoting any major relationship between the sex of the patients and their chances of being 
infected with Acinetobacter baumannii. 
 
The MIC tests showed a noticeable increase in the number of resistant bacteria to Imipenem and 
Meropenem over the year 2006 to 2008. This is concordant to other results in Kuwait (Al-Sweih 
et al., 2011) and solidifies what is already becoming a regional (Scott et al., 2007) and global 
event (Perez et al., 2007). 
 
The MIC study also showed that the highest percentage of Imipenem and Meropenem resistant 





We can clearly see a gradual increase in the overall percentage of carbapenem resistant samples, 
signifying a gradual increase in the overall resistance of Acinetobacter baumannii to 
carbapenems, in Kuwait. This slow and gradual resistance evolution could be due to several 
factors including the over-prescription of antibiotics by GPs in Kuwait, which are helping the 
bacteria to slowly evolving resistance to carbapenems, and becoming harder to treat. 
 
Acinetobacter baumannii by nature is a soil inhabiting, ubiquitous bacteria.  The rise in the 
number of outbreaks in the surrounding middle-east countries has led me to believe that dust 
winds could also have a role to play in carrying and spreading the bacterium from one place to 
another. A study showed the presence of Acinetobacter baumannii in soil samples from Iraq and 
Kuwait (Scott et al., 2007). Further environmental research needs to be conducted to see if this 
hypothesis is true. 
 
Another factor that should not be ignored is that the expatriates in Kuwait form 2/3 of the total 
population in Kuwait. Their regular travel back and forth between Asian countries such as India 
and Pakistan, and North African countries such as Egypt, could also be considered as potential 
risk factors as they may be carriers of this bacterium. 
The analysis of the phylogeny of Acinetobacter baumannii as a species along with the blaOXA-
51-like genes provided considerable evidence that within the species there are discrete lineages, 
and these lineages have been evolving independently of one another for a significant time period. 
The blaOXA-51-like genes, which are associated with these lineages, have also been co-evolving 
(Evans et al., 2007). 
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The total number of OXA samples that were sequenced was 88, with OXA-64 being the major 
OXA-type, and was found in the 44 samples. OXA-98 was found to be the second most 
prevalent, and was found in 16 samples; OXA-66 was third most prevalent, and found in 9 
samples, and OXA-71 was found in 6 samples. 
 
This study was the first to show the OXA-type distribution for Acinetobacter baumannii isolates 
from Kuwait.  The study was also the first to identify a total of 10 OXA-types to be isolated from 
the Mubarak Al-Kabeer hospital in Kuwait, which is one of the Major hospitals in Kuwait.  
To better understand the locations and relationships of each OXA-type in this study, an OXA-51-
like enzyme map taken from Evans et al. (2007) and with the OXA-types discovered in this 




































































































































































































Figure 31. Showing the OXA-51-like enzyme map, and the highlighted OXAs are the ones found 
in this study. 
 
According to the recent literature, OXA-64 in Acinetobacter baumannii samples has been 
worked on from samples from two nations so far, namely in Germany (Pfeifer et al., 2011), and 
samples from the United Arab Emirates, with the work being done at the University of 
Edinburgh by one of our fellow group members (Opazo et al., 2012). The complete gene 
sequence of OXA-64 gene was submitted and accepted by GenBank in 2005 by S. Brown and 
S.G.B. Amyes from the University of Edinburgh, under accession number: AY750907.1   
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One could speculate that one of the reasons why OXA-64 was found so readily through our study 
is because the clone was able to survive and flourish under the current circumstances at the 
hospital, and one could also speculate that if the patients were cross infected during outbreaks of 
that specific strain of Acinetobacter baumannii during their stay at the hospital.   
 
The complete gene sequence of the novel enzyme OXA-117 which is located close to the blaOXA-
98-like gene was discovered in this study, and the complete gene sequence was submitted to 
GenBank under the accession number: GQ423625.1. 
 
Using DeepView software, changes in the amino acids in each OXA type enzyme have not 
shown to have distances of less than 10Å. It was therefore concluded that the resistance or 
properties of the Acinetobacter baumannii were unaltered by the change in amino acid types, but 
rather it could be something else. We can speculate that the resistance in the isolates may be due 
to non-enzymatic mechanisms such as porin defects or efflux pumps. 
 
The PFGE results were put in a Dendogram to better understand the clonal relationship between 
each strain. We could see that almost all the OXA-64 isolates were clones, with a clonality of 
more than 80%, from the years 2006 till 2008. The same is true about OXA-98, OXA-66, and 
OXA-71 which has patterns that are the same throughout the 3 years of study. There are more 
than 80% similar and in some cases over 90%. There were no clear relatedness to the other 
OXA-types in this study; this could mean that they are not clones and that they are individual 




The 4 major clones OXA-64, OXA-71, OXA98, and OXA-66 have been able to survive and 
cross infected patients in outbreaks in the Mubarak Al-Kabeer hospital in Kuwait. One could 
also speculate that the details of the infection, where and when it occurred to the patient, could 
play a pivotal role in understanding if these four OXA-types are more wide spread in Kuwait, 
rather than just being enclosed and specific to the Mubarak Al-Kabeer hospital. Further research 
into the depth of spread and dissemination of these four OXA types in Kuwait could help us 




















We can conclude from this study VITEK-2 should not be used to identify Acinetobacter 
baumannii. Furthermore, four major clones were found in the Mubarak Al-Kabeer hospital 
during the study period, three of the clones were closely associated with those found in Europe 
and elsewhere in the world, and one new clone, OXA-117, containing a blaOXA-98-like gene that 
appears to be more prevalent in this part of Asia. This was the first study that discovered and 
characterized OXA-types in Kuwait. OXA-64 was found to be the predominant OXA-type found 
in this study. The gradual increase in resistance to carbapenems over the study period warrants 
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